Attacking COVID-19 Progression using Multi-Drug Therapy for Synergetic
  Target Engagement by Coban, Mathew et al.
Attacking COVID-19 Progression using Multi-Drug Therapy for Synergetic Target Engagement 
 
Mathew Coban1, Juliet Morrison PhD2, William D. Freeman MD3, Evette Radisky PhD1, Karine G. Le 
Roch PhD4, Thomas R. Caulfield, PhD1,5-8 
 
 
 
Affiliations 
1 Department of Cancer Biology, Mayo Clinic, 4500 San Pablo Road South, Jacksonville, FL, 32224 
USA 
2 Department of Microbiology and Plant Pathology, University of California, Riverside, 900 University, 
Riverside, CA, 92521 USA 
3 Department of Neurology, Mayo Clinic, 4500 San Pablo South, Jacksonville, FL, 32224 USA 
4Department of Molecular, Cell and Systems Biology, University of California, Riverside, 900 University, 
Riverside, CA, 92521 USA  
5 Department of Neuroscience, Mayo Clinic, 4500 San Pablo South, Jacksonville, FL, 32224 USA 
6 Department of Neurosurgery, Mayo Clinic, 4500 San Pablo South, Jacksonville, FL, 32224 USA 
7 Department of Health Science Research (BSI), Mayo Clinic, 4500 San Pablo South, Jacksonville, FL, 
32224 USA 
8Department of Clinical Genomics (Enterprise), Mayo Clinic, Rochester, MN 55905, USA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Correspondence to: 
Thomas R. Caulfield, PhD,  
Dept of Neuroscience, Cancer Biology, Neurosurgery, Health Science Research, & Clinical Genomics 
Mayo Clinic, 4500 San Pablo Road South 
Jacksonville, FL 32224 
Telephone: +1 904-953-6072,  
E-mail: caulfield.thomas@mayo.edu 
  
SUMMARY 
COVID-19 is a devastating respiratory and inflammatory illness caused by a new coronavirus that is 
rapidly spreading throughout the human population. Over the past 6 months, severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for COVID-19, has already infected over 
11.6 million (25% located in United States) and killed more than 540K people around the world. As we 
face one of the most challenging times in our recent history, there is an urgent need to identify drug 
candidates that can attack SARS-CoV-2 on multiple fronts. We have therefore initiated a computational 
dynamics drug pipeline using molecular modeling, structure simulation, docking and machine learning 
models to predict the inhibitory activity of several million compounds against two essential SARS-CoV-2 
viral proteins and their host protein interactors; S/Ace2, Tmprss2, Cathepsins L and K, and Mpro to 
prevent binding, membrane fusion and replication of the virus, respectively. All together we generated 
an ensemble of structural conformations that increase high quality docking outcomes to screen over >6 
million compounds including all FDA-approved drugs, drugs under clinical trial (>3000) and an 
additional >30 million selected chemotypes from fragment libraries. Our results yielded an initial set of 
350 high value compounds from both new and FDA-approved compounds that can now be tested 
experimentally in appropriate biological model systems. We anticipate that our results will initiate 
screening campaigns and accelerate the discovery of COVID-19 treatments. 
 
INTRODUCTION 
COVID-19 is a disease cause by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It 
was identified in Wuhan city, in the Hubei province of China in December 2019 (Chen et al., 2020; 
Huang et al., 2020; Zhu et al., 2020). The virus is spread between people via small droplets produce by 
talking, sneezing and coughing. The disease was declared a global pandemic by the World health 
organization (WHO) on March 11th, 2020. While a large proportion of the cases results in mild 
symptoms such as fever, cough, fatigues, loss of smell and taste, as well as shortness of breath, some 
cases progress into more acute respiratory symptoms such as pneumonia, multiple-organ failure, septic 
shock and blood clots. These more severe symptoms can lead to death and are likely to be precipitated 
by a cytokine storm after infection and multiplication of the virus in humans. Indeed, recent data 
indicate that the levels of IL-6 correlate with respiratory and organ failures (Gubernatorova et al., 2020). 
So far, the estimated death rate of SARS-CoV-2 is above 1.3%, which is more than 10 times higher 
than the death rate of seasonal influenza (Abdollahi et al., 2020). Older patients and patients who have 
serious underlying medical conditions such as hypertension, diabetes, and asthma are at higher risk for 
severe disease outcomes (Tian et al., 2020). A clear understanding of the genetics and molecular 
mechanisms controlling severe illness remains to be determined.  
 
SARS-CoV-2 is a positive-sense, single-stranded RNA betacoronavirus, closely related to SARS-CoV-
1, which caused severe acute respiratory syndrome (SARS) in 2003, and Middle East respiratory 
syndrome coronavirus (MERS-CoV), which caused MERS in 2012. Positive-strand RNA viruses are a 
large fraction of known viruses including common pathogens such as rhinoviruses that cause common 
colds, as well as dengue virus, hepatitis C virus (HCV), West Nile virus. The first genome sequence of 
SARS-CoV-2 was released in early January on the open access virological website 
(http://virological.org/) (Zhou et al., 2020). Its genome is ~29.8 kb and possesses 14 open reading 
frames (ORFs), encoding 27 proteins (Wu et al., 2020a). The genome contains four structural proteins: 
spike (S) glycoprotein, envelope (E) protein, membrane (M) protein, and nucleocapsid (N) protein. The 
E and M proteins form the viral envelope, while the N protein binds to the virus’s RNA genome. The 
spike glycoprotein is a key surface protein that interacts with cell surface receptor, angiotensin-
converting enzyme 2 (Ace2) mediating entrance of the virus into host cells (Zhu et al., 2018). In addition 
to its dependence on the binding of S to Ace2, cell entry also requires priming of S by the host serine 
protease, transmembrane serine protease 2 (Tmprss2). Tmprss2 proteolytically processes S, 
promoting membrane fusion, cell invasion and viral uptake (Heurich et al., 2014; Hoffmann et al., 2020). 
Blocking viral entry by targeting S/Ace2 interaction or Tmprss2-mediated priming may constitute an 
effective treatment strategy for COVID-19. The non-structural proteins, which include the main viral 
protease (nsp5 or Mpro) and RNA polymerase (nsp12), regulate virus replication and assembly. They 
are expressed as two long polypeptides, pp1a and pp1ab, which are proteolytically processed by Mpro. 
The key role of Mpro in viral replication makes it a good therapeutic target as well. A third group of 
proteins are described as accessory proteins. This group is the least understood, but its members are 
thought to counteract host innate immunity (Kim et al., 2020, Cell 181, 914–921) (Fig. 1A). 
 
There is currently no treatment or vaccine available to prevent or treat COVID-19 (Baden and Rubin, 
2020; Lurie et al., 2020) (https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-
update-daily-roundup-june-1-2020). While the FDA has granted emergency use authorization (EUA) for 
the 65-year-old antimalarial drug, hydroxychloroquine, COVID-19 treatment based on early results from 
clinical trial in China and France (Gao et al., 2020; Gautret et al., 2020a; Gautret et al., 2020b; Million et 
al., 2020), more recent results reported that hydroxychloroquine does not decrease viral replication, 
pneumonia or hospital mortality, and may in fact increase cardiac arrest in patients infected with 
COVID-19 (Mehra et al., 2020; Rosenberg et al., 2020). The accuracy of the statistical analyses in 
these studies raised serious concerns in the scientific community. More accurate data are needed to 
reach a conclusion about the effect of hydroxychloroquine in COVID-19 patients. In another recent 
study published in the New England Journal of Medicine, the antiviral remdesivir, an unapproved drug 
that was originally developed to fight Ebola, seemed to improve patients with severe breathing 
problems (Beigel et al., 2020) and has also recently been granted EUA by the FDA. Repurposing drugs 
that are designed to treat other diseases is one of the quickest ways to find therapeutics to control the 
current pandemic. Such drugs have already been tested for toxicity issues and can be granted EUA by 
the FDA to help doctors to treat COVID-19 patients.  
 
Another efficient way to attack the virus is to use drug cocktails to target multiple enzymes/pathways 
used by the virus. Combination therapy has the advantage of being less likely to select for treatment-
resistant viral mutants. Such a strategy has been successfully used to treat hepatitis C virus (HCV) and 
human-immunodeficiency virus (HIV) infections. In the case of HCV, the treatment, Enpclusa, combines 
sofosbuvir, which inhibits the viral RNA-dependent RNA polymerase (NS5B), and velpatasvir, a 
defective substrate that inhibits NS5A. Antiretroviral therapy (ART) against HIV combines drugs from 
different drug classes to target disparate aspects of the HIV replication cycle. These drug classes 
include nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, 
protease inhibitors, fusion inhibitors, CCR5 antagonists, post-attachment inhibitors, and integrase 
inhibitors. One example from HIV-AIDS literature is the randomized comparison of 4 groups of patients 
comparing monotherapy to combination therapies: zidovudine (ZDV) monotherapy; ZDV zidovudine 
and didanosine; ZDV plus zalcitabine; or didanosine monotherapy. This randomized trial showed 
positive results when ZDT was combined with didanosine or zalcitabine, and for didanosine compared 
to ZDT monotherapy in raising CD4 counts greater than 50% (Hammer et al., 1996). Combination 
therapy has become standard of care initial treatment in other infectious diseases such as 
Mycobacterium tuberculosis and failure to cure with monotherapy and requires multidrug therapy (MDT) 
(Collaborative Group for the Meta-Analysis of Individual Patient Data in et al., 2018). Similar MDT is 
also found effective in hepatitis C virus infection using glecaprevir and pibrentasivr combination 
therapies which lead to sustained virological response rates as far out as 12 weeks' post-treatment 
(Wang et al., 2019).  
 
We propose an effective combination therapy for COVID-19 could target the SARS-CoV-2 replication 
cycle at multiple levels to synergistically inhibit viral spread and dissemination. Using a computational 
pipeline that aimed to expeditiously identify lead compounds against COVID-19, we combined 
compound library preparation, molecular modeling, and structure simulations to generate an ensemble 
of conformations and increase high quality docking outcomes against two essential SARS-CoV-2 viral 
proteins and their host protein interactions; S/Ace2, Tmprss2, Cathepsin L and K, and Mpro that are 
known to control both viral binding, entry and virus replication (Fig. 1A). Our in silico approach (Fig. 
1B), which will most likely lead into experimental virus screening, structural characterization of binding 
interactions by X-ray crystallography, and compound safety profiling. Virtual screening (VS) is a rational 
driven controller for identification of new hits from compound libraries (Willett, 2006) using either ligand-
based (LBvs) or structure-based (SBvs) virtual screening (Dror et al., 2004). LBvs tactics use structural 
and biological data of known active compounds to select favorable candidates with biological activity 
from experiments (Jahn et al., 2009; Maldonado et al., 2006). SBvs approaches, on the other hand, 
examine quantitative structure-activity relationships (QSAR), clustering, pharmacophore and 3D shape 
matching (Villoutreix et al., 2007). The utility of VS is evident in the growth of our knowledge base of 
new compounds and existing drugs as well as the expansion of our structural databases. SBvs is 
generally the preferred approach when access to the target 3D-information derived from NMR, X-ray 
crystallography or homology models (Jahn et al., 2009; Maldonado et al., 2006) is possible. Molecular 
docking (docking) is the most common SBvs approach used today (Bottegoni et al., 2009; Corbeil et al., 
2012; Fernandez-Recio et al., 2005; Friesner et al., 2006; McGann, 2012; Morris et al., 2009) and 
searches for the ideal position and orientation (called "pose") of the small molecule within a target's 
binding site, which gives a score for the pose. When including knowledge of experimentally known 
compounds ("actives") from a 3D target, LBvs and SBvs can be combined to increase likelihood of 
obtaining new actives from searches (Kruger and Evers, 2010). 
 
Hit identification in VS also requires careful selection of the methods used based on the goal of the 
project (e.g. compound databases and libraries can be either proprietary, commercial or public) 
(Bender, 2010). ZINC is one such large public database often used in VS (Irwin and Shoichet, 2005), 
which contains millions of compounds. By contrast, other libraries have structure-activity relationships 
(SAR) databases (Scior et al., 2007) that integrate information about compound interactions with their 
known targets. DrugBank, Chem-Space are other attractive sources of compounds for drug 
repurposing (or repositioning) (Ashburn and Thor, 2004; Duenas-Gonzalez et al., 2008; O'Connor and 
Roth, 2005) (Wishart et al., 2008), and maintain drug diversity that is useful for scaffold development 
(Gozalbes et al., 2008; Schreiber, 2000). 
 
Advances in computing power have increased utility of in silico screening capabilities and balanced the 
need for accuracy with virtual high-throughput screening approximations and assumptions (Anthony, 
2009; Lee et al., 2008; McGaughey et al., 2007; Plewczynski et al., 2009), while recent techniques 
have improved accuracy without sacrificing CPU time (Caulfield and Devkota, 2012; Caulfield et al., 
2011; Jiang et al., 2014; MacKerell et al., 1998; Phillips et al., 2005) (Fig. 1B). Further innovations in 
docking methods have improved the exactness of empirical docking equations (Corbeil et al., 2012; 
Fernandez-Recio et al., 2005; Friesner et al., 2006; Kalid et al., 2012; Kruger and Evers, 2010; 
McGann, 2012). Accuracy is improved by incorporating molecular flexibility with simulations (Caulfield, 
2012; Caulfield et al., 2019; Caulfield and Medina-Franco, 2011; Caulfield et al., 2011; Caulfield et al., 
2014; Kayode et al., 2016), thus capturing conformational information on structural changes that 
directly impact compound docking results. 
 
Here, we present in silico screening of both the approved FDA compound library and >30 million 
compounds representing new chemical entities (NCEs) (Clecildo Barreto Bezerra et al., 2018; Ekins et 
al., 2014; Janes et al., 2018; Pillaiyar et al., 2020). Other libraries consisting of approved drugs, natural 
products, and a subset of the ZINC data base were also included based on relationship with SARS-
CoV-2 virus (Corsello et al., 2017; Lagarde et al., 2018; Riva et al., 2020)(Irwin and Shoichet, 2005). 
Our findings include >350 compounds, including both NCEs (310) and FDA repurposing compounds 
(40). Our approach combines VS and careful library selection with advanced docking techniques to 
efficiently search the behemoth chemical landscape of possible organic compounds (Bohacek et al., 
1996) and identify high value hits toward key SARS-CoV-2 targets.  
 
RESULTS 
To target the COVID19 problem on multiple fronts (e.g. Ace2:S protein, Tmprss2, Mpro, and Cathepsin L 
and K), as well as improve our screening accuracy using our selected repurposing libraries and new 
chemical entity libraries (ZINC database), we implemented a novel method that integrates protein 
flexibility/shape, adaptive biasing algorithms, machine learning from drug data, and final Z-score matrix 
weighting to our drug modeling. We matched all FDA compounds with our realistic (X-ray derived) 
protein structures over a dynamic range of protein conformations with accelerated dynamics using our 
algorithms, such as Maxwell's demon molecular dynamics (MdMD); this approach combines docking 
with simulations for exploration of both ligand and protein flexibility (Caulfield, 2012; Caulfield et al., 
2019; Caulfield and Devkota, 2012; Caulfield and Medina-Franco, 2011; Caulfield et al., 2014; Kayode 
et al., 2016; von Roemeling et al., 2018). We then refined the drug-target interface our specific leader-
like hit compounds using the quantum mechanics (QM)-based scoring within our MdMD matrix 
(Caulfield, 2012) to make our go/no-go assessment, which is particularly useful with NCEs and de novo 
compound design (DCDs). The protocol for library, structural modeling, dynamics, refinement, and hit 
identification as part of a pipeline is given (Fig. 1B). 
 
I. Modeling and Simulations for Improved Docking Outcome 
To improve our docking outcome, we constructed x-ray structure-based models of Ace2 bound to S-
protein, Mpro, and Tmprss2 in our molecular dynamics simulations (MDS) and virtual screening (Fig. 
1B,S1). As S-protein interfaces with Ace2 at a distinct region from the active site (Fig. S1A-D), 
inhibition of the binding site by ligands may disrupt the Ace2/S-protein interaction. Canonical inhibitors 
of Ace2 bind at the active site where angiotensin interacts, whereas drugs directed at the structural 
region for S-protein binding are not overlapping with the binding site. The modulation of Ace2/S-protein 
interaction by canonical Ace2 inhibitors is likely allosteric and suboptimal. Therefore, directly targeting 
the interface of the interaction should increase efficacy of the approach and block COVID viral binding, 
precluding entry (Fig. S1). Additional investigation into the glycosylation sites of the S-protein 
demonstrated that the Ace2 binding site is mostly unaffected by these additions (Fig. S2).  
 
A. S-protein:Ace2 interaction (protein-protein inhibitor, PPI) requires dynamics to reveal binding 
site 
To get the optimal interface for drug screening, we used our grid searching algorithms, as well as site 
mapping and protein-protein docking, to examine the protein-protein interactions surface using MDS 
(Fig. 2-3,S1) (Bhachoo and Beuming, 2017; Caulfield and Devkota, 2012; Caulfield et al., 2011; 
Caulfield and Harvey, 2007; Fernandez-Recio et al., 2005; Kozakov et al., 2006). The protein-protein 
inhibitor (PPI) interaction complex did not identify any immediate binding site on the surface of the PPI 
interfaces. Nevertheless, a small pore around one single beta-sheet in the center of the PPI interaction 
area could be exploited as a weak point that may perturb the interface equilibrium. Using UniProt, 
which contains information about a number of confirmed mutations, we determined the relative 
potencies of PPI binding residues, identifying those that would likely affect the integrity of the complex 
(Fig. 2). Residues K353 and Y41, which interact with D155 at the center of the PPI, are likely stabilizing 
its surface, potentially forming a useful “hot spot” for targeted druggability (Fig. 2-3,S2).  
 
To check whether this is true and to understand how Ace2:S-protein cooperation functions, we 
performed two MD simulations, one with and one without the mutation of Y41A. This mutation causes 
strict inability to form the S-protein:Ace2 complex. Analysis of the trajectory of the wild-type protein, 
which possessed an intact complex, revealed the three most stable conformations of the “hot spot” 
region with expanded pores inside the triangle of residues K353, D155, Y41. Since it is impossible to 
determine which of these three conformations is the most stable, we ran three high-throughput 
screenings based on the donor-acceptor atoms and hydrophobic areas of the region. We then 
performed three MD simulations with top pose ligands. As demonstrated in Figure 3K, ligands failed 
binding within 10 ns, while docked ligands became leaders, as determined by energetic stability, during 
MD and interaction energy values (electrostatic – red, Van der Waals - blue) (Fig. 3J/L). 
 
B. Identification of predicted inhibitors to interrupt S-protein:Ace2 PPI via docking  
To identify inhibitors of the S-protein:Ace2 interaction via docking, we used the best scoring compounds 
obtained after combination of molecular docking and molecular dynamics simulations, which feeds into 
the pipeline for constraint-based screening. The high-throughput screening (HTS) of a PPI library did 
not produce any results, since the PPI binding sites were weakly identified shallow regions (Fig. 2,4A-
D,S1). Compounds that made good insertion into the sites situated between Ace2 and S-protein were 
able to perturb the association of S-protein with Ace2 via steric hindrance of S-protein association (Fig. 
3). From the MDS, we detected compounds that decreased energy of stability between the Ace2:S-
protein complex, which is desired in an inhibitor of protein-protein interaction. As a whole, this approach 
identified a deep and narrow binding site to disturb the S-protein interaction with Ace2 (Fig. 3,4A-D). 
 
C. Tmprss2 and Mpro modeling requires dynamics to reveal optimal inhibitor binding 
To optimize the binding site of our inhibitors, we constructed a full-length (zymogen) model of Tmprss2 
(epitheliasinogen), as well as a mature version of the protease (epitheliasin), as described in our 
method section (Fig. 4E-G). The mature protease model was used for MDS studies to generate a 
reference dynamical profile that can be used to assist in silico screening of Tmprss2 inhibitors. A 
control experiment was also completed with the uncleaved (non-catalytic) form of Tmprss2 to 
demonstrate the pocket's instability and poor ligand binding capacity (Fig. S3) (Ko et al., 2015; Lucas et 
al., 2014; Wilson et al., 2005). A full-length model of monomeric Mpro was also constructed, as well as a 
homodimer (Fig. 4H-K,S1). The structure derived from PDB code 6Y2F with its ligand was used for a 
consensus virtual screen (Zhang et al., 2020). In addition, we used the dimer to generate a reference 
dynamical profile to assist with in silico screening and study its interdomain behavior.  
 
D. Tmprss2 inhibitors identified 
We acquired the dimer protein sequence from the UniProt database. BLAST search showed the 
highest identification values against factor XI, prothrombin, kallikrein proteases (~41-42%). However, 
we focused on ligands that could be active against active form of Tmprss2 protein. Thus, we found the 
ligand: (2s)-1-[(2r)-2-(Benzylsulfonylamino)-5-Guanidino-Pentanoyl]-N-[(4-
Carbamimidoylphenyl)methyl]pyrrolidine-2-Carboxamide, contained within the ChemblDB repository 
(CHEMBL1229259) and active against Tmprss2, prothrombin, and Factor XI. Likewise, another docked 
model was recovered with macrocyclic ligand (CHEMBL3699198), called: Ethyl14-[[(E)-3-[5-chloro-2-
(tetrazol-1-yl)phenyl]prop-2-enoyl]amino]-5-(methoxycarbonylamino)-17-oxo-8,16 
diazatricyclo[13.3.1.02,7]nonadeca-1(18),2(7),3,5,15(19)-pentaene-9-carboxylate. We launched several 
molecular dynamics simulations (up to 75 ns of duration) to understand the interaction with the target 
protein-binding site. Figure S3 shows the initial and stable/final states of our various models (Fig. 4E-
G). The MD analysis provided useful results for selecting the appropriate model. After 15 ns MD, the 
putative binding site collapsed (Fig. S3,4E-G). Although the active form of thrombin was used for 
Tmprss2 modeling, as a negative control we also examined the region with prothrombin-based binding 
site for completeness of the docking study (Fig. S3). The overlay of the average homology model 
structure from MD and structure 3F68 (PDB code) was used as a template to compare protein-ligand 
interaction map and assign docking constraints (Baum et al., 2009). Two optimal inhibitors for Tmprss2 
were selected for demonstration purpose in Figure 5. We also modeled Cathepsins L and K for 
preliminary work, since these can be implicated in late-endosomal entry of the virus (Fig. S4). 
 
E. Mpro inhibitors identified 
For the viral main proteinase, Mpro, a key enzyme for coronavirus replication (SARS-CoV-2), and a 
potential target for anti-SARS drug development, several peptidomimetics synthetized in early 2012 
against SARS-CoV-1 proteases were identified as selective. There is a high degree of sequence 
identity between the SARS-CoV-1 and SARS-CoV-2 Mpro. This means that SARS-focused ligands 
could form similar interaction map with Mpro protein and offers good launching points for 3D-
QSAR/Machine Learning-drive based drug design for future iterations. To perform the virtual screening, 
protein structure was taken from the PDB code 7BQY complex and significant attention was paid to the 
interaction between the crystallized ligand from the complex and protein-binding site (Jin et al., 2020) 
(Fig. 6). As the binding site is quite large (Fig. 6A) we used a set of additional crystal structures (PDB 
code 6Y2F and fragment-like compounds from https://www.diamond.ac.uk/) to narrow the source of 
possible conformations. The binding of the compounds inserted into this region demonstrated a very 
canonic and recurring interacting motif, represented with α-Keto amide group flanked with aliphatic or 
saturated rings.  We then performed molecular dynamics of 75 ns for the ligand-free dimer structure of 
the Mpro to evaluate and “catch” the most flexible elements of the binding site. Our simulation revealed 
that the extended binding pocket was not very stable, unlike its individual sub-pocket, which contains 
active cysteine (C145) residue (Fig. 6B,6C). We began our molecular docking after assigning several 
combinations of constraints that should define specific interactions with the protein-binding site. We 
performed several high-throughput screening procedures using the same set of features in different 
combinations of constraints by partial matching algorithm (Fig. 6D-E). We then ranged docking scores 
and compared obtained conformations inside the binding site with the co-crystalized ligands from 
7BQY, 6Y2F structures to select the most potent compounds. 
 
II. Analysis of Identified Compounds 
By disrupting the SARS-CoV-2 viral process in three different critical routes: Binding, Entry, and 
Replication with our virtual screening approaches against dynamic structures, we were able to identify 
350 compounds (Dataset S1) and compile data reflecting physiochemical and chemoinformatic 
properties. An exemplar top hit from each target is summarized for docking score in Table 1. To 
classify the compounds and their chemical space, we completed various regression, K-means analyses 
and fingerprint measurements, and provide further details about their structures and properties, 
including commonly evaluated traits: MW, HBA, HBD, docking score, Rule of Three (Jorgensen), Rule 
of Five (Lipinksi), logPo/w, and logS (Dataset S2). We focused on new compound searches. The MW for 
these initial screening compounds ranges from large fragment (~250 Da) to mature drug sized 
molecules (~500 Da) with only 10 of the 310 top scoring compounds being over 500 Da in size and the 
smallest fragment-based compound measured 178 Da. Overall the docking scores were very good with 
median around -7 kcal/mol using the Glide XP calculations. We also generated a list of most commonly 
related drugs and discuss some of our best hits to known and clinical trial drugs (Dataset S3). The 
general process for pruning the >30 million total chemical fragments and compounds from 
commercially available compounds for the initial round of virtual screening is described (Fig. 1B), which 
reduces the primary large set to 3 million per conformation of target.  
 
Table 1. Top 40 FDA predicted compounds for Ace2:S protein, MPro, and Tmprss2. 
Drug Synonyms 
Predicted 
Protein 
In Silico 
Score Target CAS 
Metaproterenol 
sulfate 
Orciprenaline 
Sulfate Ace2 -8.05 Others 
5874-97-
5 
Isoprenaline HCl 
Isuprel, 
Isadrine, 
Euspiran, 
Proternol, NSC 
37745, NSC 
89747  Ace2 -7.44 
Adrenergic 
Receptor 51-30-9 
Epinephrine HCl N/A Ace2 -7.12 
Adrenergic 
Receptor 55-31-2 
Levosulpiride N/A Ace2 -6.87 
Dopamine 
Receptor  
23672-
07-3 
Metaraminol 
bitartrate 
Metaradrine 
Bitartrate Ace2 -6.84 Others 
33402-
03-8 
Valganciclovir HCl N/A Ace2 -6.58 
Antifection 
(Anti-infection) 
175865-
59-5 
Isoprenaline HCl 
Isuprel, 
Isadrine, 
Euspiran, 
Proternol, NSC 
37745, NSC 
89747  Ace2 -6.45 
Adrenergic 
Receptor 51-30-9 
S4817 Atenolol 
Tenormin, 
Normiten, 
Blokium Ace2 -6.35 
β1 receptor, β2 
receptor 
29122-
68-7 
S3783 
Echinacoside N/A Ace2 -6.09 Others 
82854-
37-3 
Propafenone 
Rythmol SR, 
Rytmonorm Ace2 -6.04 
Sodium 
Channel 
34183-
22-7 
Amikacin sulfate BB-K8 Ace2 -5.98 Antifection 
39831-
55-5 
Pro-chlorperazine 
dimaleate salt 
Prochlorperazin, 
Compazine, 
Capazine, 
Stemetil Ace2 -5.79 
Dopamine 
Receptor 30718 
Isoetharine 
mesylate N/A Ace2 -5.47 Others 
7279-75-
6 
Levosulpiride N/A Ace2 -6.87 
Dopamine 
Receptor  
23672-
07-3 
S5023 Nadolol 
Corgard, Solgol, 
Anabet Ace2 -5.16 
Androgen 
Receptor 
42200-
33-9 
Benserazide HCl Ro-4-4602 Ace2 -5.93 
Dopamine 
Receptor 
14919-
77-8 
S3694 
Glucosamine (HCl) 
2-Amino-2-
deoxy-glucose 
HCl Ace2 -5.57 Others 66-84-2 
S4701 2-Deoxy-D-
glucose 
2-deoxyglucose, 
NSC 15193 Ace2 -5.18 Others 154-17-6 
Inulin N/A Ace2 -5.18 Others 
9005-80-
5 
Cephalexin 
Alcephin, 
Cefablan, 
Keflex, Cefadin, 
Tepaxin Ace2 -5.11 Antifection 
15686-
71-2 
S4722 (+)-
Catechin 
Cianidanol, 
Catechinic acid, 
Catechuic acid MPro -6.73 Others 154-23-4 
S4723 (-) 
Epicatechin 
L-Epicatechin, (-
)-Epicatechol 
MPro 
-6.32 Others 490-46-0 
S5105 
Proanthocyanidins 
condensed 
tannins 
MPro 
-6.19 Others 
20347-
71-1 
Carbenicillin 
disodium N/A  
MPro 
-5.78 Antifection 
4800-94-
6 
AG-120 
(Ivosidenib) N/A 
MPro 
-5.52 Dehydrogenase 
1448347-
49-6 
Atorvastatin 
calcium N/A 
MPro 
-5.39 
HMG-CoA 
Reductase 
134523-
03-8 
Bezafibrate N/A 
MPro 
-4.93 PPAR 
41859-
67-0 
PF299804 N/A 
MPro 
-4.34 EGFR 
1110813-
31-4 
Bumetanide Bumex Tmprss2 -6.5 Others 
28395-
03-1 
Aloin Barbaloin Tmprss2 -6.45 Tyrosinase 
1415-73-
2  
Salbutamol sulfate 
Ventolin, 
Asthalin, 
Asthavent Tmprss2 -6.1 
Adrenergic 
Receptor 
51022-
70-9 
S4953 Usnic acid Usniacin Tmprss2 -5.8 Others 125-46-2 
Avanafil N/A Tmprss2 -5.62 PDE 
330784-
47-9 
S3612 Rosmarinic 
acid Rosemary acid Tmprss2 -5.6 IKK-β 
20283-
92-5 
S5105 Proantho-
cyanidins 
Condensed 
tannins Tmprss2 -5.51 Others 
20347-
71-1 
Ractopamine HCl N/A Tmprss2 -5.22 Others 
90274-
24-1 
Neohesperidin 
dihydrochalcone 
Neohesperidin 
dhc  Tmprss2 -5.2 Others 
20702-
77-6  
Cidofovir Vistide Tmprss2 -5.18 Others 
113852-
37-2 
Zidovudine azidothymidine Tmprss2 -5.02 
Reverse 
Transcriptase 
30516-
87-1 
 
As an example, when examining some prototype compounds from our selected dataset of >300 NCEs 
screened from >10 million total compounds, we find the predicted interactions between drug and 
protein (Table S2) have some common binding modalities. When looking at the dynamical data for the 
drugs binding to the protein-protein site on Ace2, we find the RMSD, RMSF, and H-bond occupancy 
evidence strong binding capability, as calculated from three separate simulations of Ace2 with different 
ligands, referred to as 300, 392, and 488 (Fig. 4,S1). These observations can be applied to generate 
constraints for additional virtual screening to improve the performance at higher throughput. Based on 
these results, ligand 392 reduced the overall RMSD and per residue RMSF, while maintaining strong 
hydrogen bonds, as demonstrated by its greater occupancy during the simulation (Table S1). This 
information, particularly H-bond occupancy and modulation of interface residue RMSFs, can be used in 
conjunction with docking and other data to profile the compounds more thoroughly (Fig. 4). In some 
cases, where constraints were utilized, the docking score underrepresents the compound and testing is 
needed to get important single-point data to clarify actives from non-actives, as well as determine the 
real IC50s for the selected active compounds. We will enrich our dataset with the top compounds for 
future rounds of parallel chemical screening and eventual de novo chemical design for novel chemical 
entities. Current results of our approach are presented on all three targets (Ace2, Tmprss2, MPro). 
 
III. Screening FDA-approved drugs for repurposing to minimize delay towards clinical benefit 
For each of our targets, we screened for hits from a library of FDA-approved compounds alongside the 
more extensive library of NCEs. Our final result across all three targets identified a total of 350 specific 
compounds, with 167 against Ace2, 40 against Tmprss2, and 103 against Mpro. Among these are FDA-
approved drugs that could be repurposed: 21 against Ace2, 11 against Tmprss2, and 8 against Mpro 
(Supplemental Dataset TableS1_topNCE-FDA-hits.xlsx). 
 
A. Ace2 Repurposing Drugs (FDA set) 
Isoprenaline hydrochloride (isoprotenerol) is an adrenoreceptor agonist that can be repurposed as a 
vasopressor to augment cardiovascular function with a beta-receptor side benefit of bronchodilation to 
improve breathing function. Metaraminol bitartrate, a stereoisomer of meta-hydroxynorephedrine, is a 
potent sympathomimetic amine to raise blood pressure. Atenolol and nadolol are beta-receptor blocking 
agents used in chronic hypertension, a comorbid risk factor in COVID-19 patients. Propafenone is an 
anti-arrhythmic agent approved for patients with life-threatening ventricular tachycardia. Levosulpiride is 
an atypical antipsychotic medication with prokinetic function that can be used in patients with agitated 
delirium, and gut immotility. Valganciclovir hydrochloride is an antiviral agent used for cytomegalovirus 
(CMV), varicella zoster virus (VZV), and preventative medication in HIV patients (Wu et al., 2020b). 
Recent data shows COVID-19 deplete CD8 T helper cells similar to HIV (Zheng et al., 2020). Amikacin 
sulfate and cephalexin are antibiotic anti-bacterial drugs that can treat bacterial super-infection. 
Prochlorperazine dimaleate is a phenothiazine derivative prescribed in medicine for nausea. 
Isoetharine mesylate is a selective adrenergic beta-2 agonist and fast-acting aerosolized bronchodilator 
for COVID-19 respiratory distress. Benserazide hydrochloride is an aromatic L-amino acid 
decarboxylase (DOPA decarboxylase inhibitor) used with levodopa for the treatment of Parkinsonism. 
Glucosamine hydrochloride is constituent found in cartilage and used for osteoarthritis joint pains. 
S4701 or 2-Deoxy-D- glucose (2D-DG) compound can induce ketogenic state, a powerful pathway 
involved in reducing systemic inflammation. Inulin is a natural prebiotic agent that enhances GI function 
and digestion by increasing prebiotic GI homeostasis critical to stabilize downstream anti-inflammatory 
effects and prevent overgrowth of harmful bacteria. Metaproterenol is a bronchodilator (beta-2 receptor 
agonist) that is commonly used to treat a variety of respiratory disorders including asthma, COPD, 
bronchitis and wheezing associated with viral pneumonias in clinical practice. The novelty of this drug is 
that is aerosolized and can be given as a breathing treatment and similar reach the lungs, which have a 
tremendous surface area and enter the blood rapidly. By inhalation this drug acts rapidly and potentially 
with or in combination with other aerosolized drugs or oral or IV combination drugs. Its inhalational 
route of delivery also can reach alveolar type II cells which express Ace2 for dual synergism. 
Metaraminol bitartrate, a stereoisomer of meta-hydroxynorephedrine, is a potent sympathomimetic 
amine. This drug is used in patients with hypotension or low blood pressure. COVID-19 hospitalized 
patients in the intensive care unit (ICU) setting often need vasopressor agents to raise blood pressure 
in a condition called shock (dangerously low blood pressure) from COVID-19 disease or sepsis. 
Therefore, metaraminol has dual purpose of antiviral function at Ace2 docking site /entry as well as 
helping with systemic blood pressure in those acutely ill COVID-19 patients. This drug has immediate 
repurposing use in this patient population. 
 
B. Mpro Repurposing Drugs (FDA set) 
Atorvastatin is a statin drug with anti-inflammatory, immunomodulatory (Diamantis et al., 2017) and 
endothelial benefits (Ackermann et al., 2020; Varga et al., 2020). Carbenicillin disodium is a penicillin 
derivative antibacterial antimicrobial agent. Catechins are derived from plants with many beneficial 
properties in human health including anticancer, anti-obesity, antidiabetic, anti-cardiovascular, anti-
infectious, hepatoprotective, and neuroprotective effects (Isemura, 2019). These substances fall 
outside FDA purview since supplements and generally have a wide safety margin that will be tested on 
the multidrug platform. Epicatechine S5105 is a naturally occurring flavonoid found in chocolate with 
anti-sarcopenic effects on skeletal muscle (Gutierrez-Salmean et al., 2014). Ivosidenib is an 
experimental drug for treatment of several forms of cancer. Bezafibrate is a fibrate lipid-lowering drug, 
which creates a favorable anti-inflammatory ratio against cardiovascular diseases. PF299804 or 
dacomitinib is an EGFR inhibitor used in cancer therapeutics. Metaproterenol is a bronchodilator (beta-
2 receptor agonist) that is commonly used to treat a variety of respiratory disorders with viral 
pneumonias in clinical practice. Carbenicillin disodium is a penicillin derivative antibacterial 
antimicrobial agent that as mentioned above can be used in conjunction with other anti-SARS-Cov-2 
agents to shut down antiviral effects and used in combination with those COVID-19 patients with 
secondary super-infection with bacterial infection of lung, blood, or skin. 
 
C. Tmprss2 Repurposing Drugs (FDA set) 
Bumetanide is a loop-diuretic used to remove extra fluid in the body (edema) such as pulmonary 
edema. Aloin is an anthraquinone glycoside found naturally in aloe vera plants, a natural cathartic, and 
decreases 16s rRNA sequencing of dysbiosis-producing butyrate producing bacterial species via an 
emodin breakdown product (Gokulan et al., 2019). Emodin blocks Ace2 and viral docking (Ho et al., 
2007). Salbutamol sulfate (albuterol) is a bronchodilator used in various breathing disorders. S4953 
usnic acid is a naturally occurring dibenzofuran derivative found in lichen plant species, in some 
kombucha teas, with adrenergic function to raise blood pressure and potential bronchodilator. Usnic 
acid is an active ingredient in some and a preservative in others and has a wide array of antimicrobial 
action against human and plant pathogens with antiviral, antiprotozoal, antiproliferative, anti-
inflammatory, and analgesic activity (Ingolfsdottir, 2002). Avanafil is a class of medications called 
phosphodiesterase (PDE) inhibitors, which are pulmonary artery and circulation dilators. S3612 
Rosmarinic acid is a naturally occurring compound found in plants (rosemary and sage), which has 
broad range of antimicrobial activity including antiviral activity including HIV (Shekarchi et al., 2012). 
Ractopamine is a beta-agonist function used for bronchodilatation. Neohesperidin dihydrochalcone 
(NHDC) is a naturally derived plant sweetener (bitter orange) with anti-Tmprss2 effects. Cidofovir and 
zidovudine (ZDV) are both antiviral drugs used in HIV patients.  
 
 
DISCUSSION 
 
Clinical Unmet Need for COVID-19 Acute Therapeutics 
There is a critical unmet patient need for therapeutics to treat the acute phase of COVID-19 disease 
now and for the future. Efforts to create and trial a vaccine are underway, but 11.6 million patients are 
confirmed infected globally (>540K deaths) with 25% infected within the United States and we are just 
at the midpoint of 2020. Therefore, there is an urgent need to rapidly speed drug discovery from the 
bench to the bedside. In order to accelerate drug discovery, translation and human application, a 
design funnel using high-powered artificial intelligence is needed to screen millions of compounds 
against macromolecular mechanistic targets against the virus. At the back end of this funnel 40 drug 
candidates emerged, many of which may represent repurposing candidates for use in humans due to 
known safety and tolerability profiles. However, the approach with the highest probability of overall 
clinical therapeutic success may be not a single drug therapy for this viral RNA disease but rather a 
multi-pronged drug approach gleaned from decades of HIV-AIDS epidemic research. A multidrug 
approach for HIV has improved survival, markedly reduced viral loads, and vastly improved 
management of the disease by preventing AIDS end-stage fatal complications. We therefore suggest 
that a multifaceted drug approach for SARS-Cov-2 may prove superior by attacking 3 viral entry and 
replication cycle sites simultaneously: Ace2 receptor docking site and entry, Tmprss2 endosomal 
packaging, and MPro viral replication. Multiple drug targets for each of the 3 sites also allow 
permutations and optimization for combinatorial success. 
 
Comparison of FDA compounds identified from other recent screening 
A recent study that screened commercially available >10,000 clinical-staged and FDA-approved small 
molecules against SARS-CoV-2 in a cell-based assay (Riva et al., 2020) identified interesting 
compounds for alternative targets that complement our results. These FDA approved compounds 
included MDL-28170, a selective Cathepsin B inhibitor; VBY-825, a non-specific Cathepsin B, L, S, V 
inhibitor; Apilimod, an inhibitor of production of the interleukins IL-12 and IL-23; Z-LVG-CHN2, a tri-
peptide derivative inhibitor for cysteine proteinases; ONO 5334, a selective Cathepsin K inhibitor; and 
SL-11128, a polyamine analogs designed against E. cuniculi, a antimicrobial agents used as an 
adjuvant treatment for opportunistic AIDS-associated infections. Overall these compounds are 
Cathepsin-centric or antibiotic in nature, with little to no effect on our intended targets (Tmprss2, Ace2, 
MPro). Additional top hits identified by Riva et al. include: AMG-2674, an AMGEN compound inhibitor of 
TRPV-1 (Vanilloid Receptor); SB-616234-A that possesses high affinity for human 5-HT1B receptors; 
SDZ 62-434 that strongly inhibited various inflammatory responses induced by lipopolysaccharide 
(LPS) or function-activating antibody to CD29; Hafangchin A (also called "Tetrandrine"), a bis-
benzylisoquinoline alkaloid, which acts as a calcium channel blocker; Elopiprazole an antipsychotic 
drug of the phenylpiperazine class (antagonist at dopamine D2 and D3 receptors and an agonist at 
serotonin1A receptors) that was never marketed; YH-1238, which inhibits dipeptidyl peptidase IV (DPP-
IV) enzyme prolonging the action of the incretin hormones, glucagon-like peptide-1 (GLP-1) and 
glucose-dependent insulinotropic polypeptide (GIP); KW-8232, an anti-osteoporotic agent that can 
reduce the biosynthesis of PGE2; Astemizole, an antihistamine; N-tert-butyl Isoquine (also called 
"GSK369796"), an antimalarial drug candidate; and Remdesivir, a broad-spectrum antiviral medication 
developed by the biopharmaceutical company Gilead Sciences. Again, none of these compounds were 
geared toward targeting Tmprss2 or Mpro, and are also not specific to Ace2. While the lack of overlap 
may be surprising, results generated by Riva and colleagues are not in opposition to our findings and 
both approaches can complement each other. Most importantly, these approved FDA compounds can 
be combined with our set of identified NCE (310 compounds) that have been demonstrated to have low 
toxicity issues based on our chemoinformatics filtering (Fig. 1B). All NCE compounds identified were 
chemical moieties that do not overlap any FDA drugs. Altogether, the data presented here 
complements previously generated data and should help prioritize and rapidly identify safe treatments 
for COVID-19. Future work will rely on advanced 3D-QSAR, fragment-based drug design principles for 
de novo drug optimization. 
 
Selective AI-SARS-Cov-2 Targeting and Drug Repurposing Data - Ace2, Tmprss2, Mpro  
Among millions of potential COVID-19 drugs screened the majority of the final 40 drug candidates have 
known medical use and/or FDA approval for a primary indication (e.g., hypertension, cardiac indication, 
hyperlipidemia) with well-established patient safety and tolerability profiles from large phase III human 
trials and post- market (Phase IV) analyses. These large human data provide both a clinically 
significant and scientifically innovative window of opportunity to test 40 compounds on the multidrug 
platform, and, in conjunction, observe longitudinal human survival outcomes of COVID-19 patients on 
these drugs for comparative effectiveness within established and ongoing patient registries. An 
emerging example of this important parallel is Ace2 pathway drugs (Ace inhibitors [AceI] and 
angiotensin receptor blocking drugs [ARB]), which are increasingly observed in humans with COVID-19 
to be associated with improved survival advantage (Jarcho et al., 2020; Mancia et al., 2020; Mehta et 
al., 2020; Patel and Verma, 2020; Vaduganathan et al., 2020). However, there is a scientific knowledge 
gap within human registries data regarding a scientifically robust and testable translational platform to 
test mechanistic effects of these different molecular compounds. Therefore, creation of a “pandemic 
platform” using newer technology of compound AI drug throughput screening combined with animal 
multi-drug screening models creates an early Phase I/II safety, tolerability and early efficacy platform 
which is rapidly needed to expedite bedside human use for COVID-19 pandemic, and as a platform that 
can be used in future pandemics. 
 
NCE set of compounds 
A flurry of activity to identify compounds for SARS CoV-2 targets has been underway by academic labs 
globally. Here in our approach we introduce our novel Maxwell's demon molecular dynamics method for 
screening flexibility required to get rare and essential conformational transitions and pathways to find 
the most likely druggable state. We also used our quantum docking technique (QM-driven adaptive 
molecular dynamics scanning docking) (Caulfield, 2012) to identify compounds effective for targeting 
Ace2, Tmprss2 and Mpro. The compounds identified by our large-scale in silico platform can next be 
experimentally validated as binders for intended targets and for efficacy in models of the disease, 
evaluated for EC50/safety-toxicity data, and carried into hit-to-lead and lead optimization in a drug 
development pipeline. Structural studies such as X-ray crystallography will also be important to 
generate structural SAR data for these efforts. 
 
In sum, our leading edge in silico methods incorporating structural dynamics have produced a set of 
350 candidate compounds suitable for screening in biological disease models. Among these, 40 FDA-
approved compounds are eligible for rapid clinical trial testing. Additionally, our results bring forward 
310 NCEs predicted to possess potency and specificity for viral or human accessory target proteins to 
lower the viral load. Moreover, this resource offers the community a set of chemical tools to probe the 
behavior of these enzymes essential for SARS-CoV-2 progression, namely, binding, entry and 
replication. As SARS-CoV-2 is already endemic, the rapid identification of effective antivirals remains a 
paramount focus until we have an efficient vaccine to provide long-lasting protection.  
 
 
  
STAR*METHODS 
I. General Modeling Methods 
In general, COOT was used for building in missing residues and regularizing geometry (Emsley and 
Cowtan, 2004; Emsley et al., 2010). More details for the preparation of each model are given in the 
respective subsections. Since these structures were all used in downstream computational studies, a 
uniform structural preparation was implemented. The full-length structures are comprised of all residues 
and side chains. We added missing atoms in rotamers and de-clashed atoms, added missing residues 
for chain continuity, and removed extraneous molecules/atoms (e.g. artifacts of crystallography or 
alternative conformations of residues were removed (keeping the highest occupancy)), and the B-
factors were set to isotropic. The PDBePISA server was used to data mine the interface between Ace2 
and S-protein (Krissinel and Henrick, 2007). Surface interactions data is provided (Supplemental).  
Calculations on molecular dynamics trajectories including RMSD, RMSF, and H-bonds were performed 
using VMD and internal tools thereof (RMSD trajectory tool and Tk Console). Prior to calculations, the 
backbone (CONCα) atoms of each frame of the trajectories were aligned to the first frame as a 
reference, to remove the effect of random rotation/translation. After alignment, the per residue average 
of RMSF or RMSD per frame in Å across the entire MDS trajectory is given. For the Ace2-ligand 
simulations, the number of hydrogen bonds between the protein and ligand were recorded for each 
frame, and the occupancy of each specific H-bond is defined as the percentage of frames the bond is 
present. RMSD, RMSF, and H-bond data were plotted in 2D format in Excel. The RMSF was also 
appended to the beta column of the PDB and heat-mapped to the structure using a custom Tcl/Tk script 
and PyMOL. All molecular graphics were generated in PyMOL (Mooers, 2016).  
 
II. General Dynamics Conditions 
Molecular Dynamics and Monte Carlo simulations were performed on the protein to allow local regional 
changes for full-length structure for all acids of each structure. 
The X-ray refinement for Monte Carlo was built using YASARA SSP/PSSM Method (Altschul et 
al., 1997; Hooft et al., 1996a; Hooft et al., 1996b; King and Sternberg, 1996; Krieger et al., 2009; Qiu 
and Elber, 2006). The structure was relaxed to the YASARA/Amber force field using knowledge-based 
potentials within YASARA. The side chains and rotamers were adjusted with knowledge-based 
potentials, simulated annealing with explicit solvent, and small equilibration simulations using 
YASARA’s refinement protocol (Laskowski RA, 1993). The entire full-length structure was modeled, 
filling in any gaps or unresolved portions from the X-ray. 
Refinement of the finalized models was completed using either Schrodinger’s LC-MOD Monte 
Carlo-based module or NAMD2 protocols. These refinements started with YASARA generated initial 
refinement of Tmprss2 (Altschul et al., 1997; Hooft et al., 1996a; Hooft et al., 1996b; Krieger et al., 
2009). The superposition and subsequent refinement of each protein regions yields a complete model. 
The final structures were subjected to energy optimization with PR conjugate gradient with an R-
dependent dielectric.  
Atom consistency was checked for all amino acids of the full-length wild-type structure, verifying 
correctness of chain name, dihedrals, angles, torsions, non-bonds, electrostatics, atom typing, and 
parameters. Model was exported to the following formats: Maestro (MAE), YASARA (PDB). Model 
manipulation was done with Maestro (Macromodel, version 9.8, Schrodinger, LLC, New York, NY, 
2010), or Visual Molecular Dynamics (VMD) (Humphrey et al., 1996). 
MDS and MC searching were completed on each model for conformational sampling, using 
methods previously described in the literature (Caulfield and Devkota, 2012; Caulfield and Medina-
Franco, 2011; Caulfield, 2011; Caulfield et al., 2011). Briefly, each protein system was minimized with 
relaxed restraints using either Steepest Descent or Conjugate Gradient PR, then allowed to undergo 
the MC search criteria, as shown in the literature (Caulfield and Devkota, 2012; Caulfield and Medina-
Franco, 2011; Caulfield, 2011; Caulfield et al., 2011). The primary purpose of MC, in this scenario, is 
examining any conformational variability that may occur with each protein. 
 
III. Structural modeling Ace2/S-protein 
 For Ace2/S-protein, PDB code 6VW1 was used to construct the model (Shang et al., 2020). While the 
structure was mostly complete, chain F (S-protein) was missing more residues, though it had residue 
Ala522. Chain E (S-protein) was only missing residue 522. Residue Ala522 was built into chain E using 
COOT and where the extraneous molecules (solvent/cryoprotectant) and chains were deleted to leave 
only the heterodimer Ace2/S-protein, which was processed to be used for computational studies, not to 
generate a de novo model or complete structure with missing atoms and sections. 
 All information about the protein was found on the corresponding Uniprot page. After identifying the hot 
spot residues using SiteMap or protein-protein interfaces, we used MD to find out how the Y41A 
mutation can affect of PPI inhibition. We performed MD for wild type and mutated protein. Residual 
mutation was also performed using PyMol's built-in tools. Gromacs 2018 and amber99 force field were 
used to conduct MD and further analysis of the results (Baugh et al., 2011; Dilip et al., 2016; Janson et 
al., 2017; Makarewicz and Kazmierkiewicz, 2013, 2016; Mooers, 2016). Visual inspection of every 10 
frames allowed us to determine some tendency of structural deformation in a certain place on the 
protein surface. According to the literature data and our finding, we focused on the predicted binding 
site. Then, each trajectory was analyzed via the built-in clustering tool based on the RMSD distribution. 
Three the most stable conformations of the binding site were chosen for the docking studies. All 
received docking poses from each docking study were evaluated based on the docking scores, 
interaction diagrams and solvent exposure. To make some prediction regarding the binding method, we 
carried out another molecular dynamics simulation for the upper poses of each docking. After such a 
confirmation of our assumptions, we selected the most powerful and accurate compounds from the 
results of docking.  
 
IV. Structural modeling Tmprss2 
A homology model was constructed on the basis of prothrombin crystal structure in complex with the 
ligand analog (PDB code 3F68) (Baum et al., 2009). We modeled the 492 amino acid Tmprss2 protein 
two different ways: YASARA based and SwissModel server based (Krieger et al., 2002; Waterhouse et 
al., 2018; Zoete et al., 2011). First, the YASARA based model begins with the FASTA sequence: 
MALNSGSPPAIGPYYENHGYQPENPYPAQPTVVPTVYEVHPAQYYPSPVPQYAPRVLTQASNPVVCT
QPKSPSGTVCTSKTKKALCITLTLGTFLVGAALAAGLLWKFMGSKCSNSGIECDSSGTCINPSNWCDG
VSHCPGGEDENRCVRLYGPNFILQVYSSQRKSWHPVCQDDWNENYGRAACRDMGYKNNFYSSQGI
VDDSGSTSFMKLNTSAGNVDIYKKLYHSDACSSKAVVSLRCIACGVNLNSSRQSRIVGGESALPGAWP
WQVSLHVQNVHVCGGSIITPEWIVTAAHCVEKPLNNPWHWTAFAGILRQSFMFYGAGYQVEKVISHPN
YDSKTKNNDIALMKLQKPLTFNDLVKPVCLPNPGMMLQPEQLCWISGWGATEEKGKTSEVLNAAKVLL
IETQRCNSRYVYDNLITPAMICAGFLQGNVDSCQGDSGGPLVTSKNNIWWLIGDTSWGSGCAKAYRP
GVYGNVMVFTDWIYRQMRADG. Topological domains have the following characteristics: residues 1 – 
84 forms the cytoplasmic sequence; residues 85 – 105 form the transmembrane domain region (helical 
21 aa); and residues 106 – 492 form the Signal-anchor for type II membrane protein (extracellular), 
where the protein as two main chains: non-catalytic chain (Met1-Arg225) and catalytic chain (Ile256-
Gly492), where each domain modeled as a separate unit built together in composite. Disulfide bonds 
exist between several residues (113 ↔ 126), (120 ↔ 139), (133 ↔ 148), (172 ↔ 231), (185 ↔ 241), 
(244 ↔ 365), (281 ↔ 297), (410 ↔ 426), (437 ↔ 465), which can be informative for building the 
structure. Glycosylation sites are also possible at residues N213 and N249. Cleavage site (active) 
exists between Arg255 and Ile256 (see refinement section). 
The second method, homological modeling was performed using the SwissModel server after 
performing a BLAST search on available protein structures in the RCSB database. Molecular dynamics 
simulations of 100 ns of both, suggested and re-modeled protein structures, was performed with 
GROMACS 2018 (Makarewicz and Kazmierkiewicz, 2013, 2016). Based on the structural analysis and 
the generated Connolly surfaces, we identified critical changes in the binding site of the proposed 
model and began creating a mesh for the binding site of the new homology model. Since our model 
was based on the structure of thrombin, we used its co-crystallized ligand as a template for assigning 
constraints and ensured we built the catalytically active state. 
 
V. Structural modeling Mpro 
For Mpro (PDB 6Y2F) co-crystallization with tert-butyl (1-((S)-1-(((S)-4-(benzylamino)-3,4-dioxo-1-((S)-2-
oxopyrrolidin-3-yl)butan-2-yl)amino)-3-cyclopropyl-1-oxopropan-2-yl)-2-oxo-1,2-dihydropyridin-3-
yl)carbamate (also referred to as alpha-ketoamide 13b) was used; the structure was also mostly 
complete. Residues E47 and D48 were built in using COOT, where the other preparations previously 
described were also performed. To build the missing residues, the coordinates and structure factors 
were downloaded, generated 2mFo-DFc and FEM maps, and real space refine zone/regularize zone 
were used to fit to electron density and optimize local geometry. The ligand (alpha-ketoamide 13b) was 
left for usage as a cognate ligand for virtual screening. 
The protein structure was initially studied using MD to find out if the binding site is cruel enough 
or can break down without a ligand molecule during the simulation. Simulation of the dimeric complex 
for 100 ns was sufficient to compare conformational changes from different MD states. A set of 
positional and hydrogen bonds were assigned based on the available peptidomimetic structure. Thus, 
two screenings were conducted with an emphasis on positional constraints or interactions of hydrogen 
bonds. 
 
VI. Structure-refinement of Ace2 (S-protein:Ace2), Tmprss2, and Mpro Models 
Using MDS and MC refinement with Schrodinger and/or YASARA SSP/PSSM methods 
(Altschul et al., 1997; Hooft et al., 1996a; Hooft et al., 1996b; King and Sternberg, 1996; Krieger et al., 
2009; Qiu and Elber, 2006), each structure was relaxed to the YASARA/Amber force field using 
knowledge-based potentials within YASARA. The side chains and rotamers were adjusted with 
knowledge-based potentials, simulated annealing with explicit solvent, and small equilibration 
simulations using YASARA’s refinement protocol (Laskowski RA, 1993). The entire full-length structure 
was modeled, filling in any gaps or unresolved portions from the X-ray structure. 
Refinement of the finalized models was completed using either Schrodinger’s Monte Carlo-
based module or in-house protocols. These refinements started with generated initial refinement for 
each independent structure (Altschul et al., 1997; Hooft et al., 1996a; Hooft et al., 1996b; Krieger et al., 
2009). The superposition and subsequent refinement of the overlapping regions yields a complete 
model for all four proteins. The final structures were subjected to energy optimization with PR conjugate 
gradient with an R-dependent dielectric.  
Atom consistency was checked for all amino acids (and atoms) of the full-length wild-type 
model, verifying correctness of chain name, dihedrals, angles, torsions, non-bonds, electrostatics, atom 
typing, and parameters. A multimeric-complex model is predicted, including cofactors and ions. All of 
the models were exported in the following formats Maestro (MAE), YASARA (PDB). Model 
manipulation was done with Maestro (Macromodel, version 9.8, Schrodinger, LLC, New York, NY, 
2010), or Visual Molecular Dynamics (VMD) (Humphrey et al., 1996). Analyses were emphasized on 
the protein-protein interaction regions containing. 
Monte Carlo dynamics searching (MC-search) was completed on each model for additional 
conformational sampling, using methods previously described in the literature (Caulfield and Devkota, 
2012; Caulfield, 2011; Caulfield et al., 2011). Briefly, each protein system was minimized with relaxed 
restraints using either Steepest Descent or Conjugate Gradient PR, then allowed to undergo the MC 
search criteria, as shown in the literature (Caulfield and Devkota, 2012; Caulfield, 2011; Caulfield et al., 
2011). The primary purpose of MC, in this scenario, is examining any conformational variability that 
may occur with different orientations in the region near to protein-protein interfaces. 
 
VII. MD Simulation Protocol 
The total atomic force field was used to minimize the energy of the system, namely, the descent 
algorithm for 20,000 steps with an iteration interval of 2 fs. The equilibrium of the solvent was carried 
out using positional restrictions imposed on the atoms of protein structures, while the solvent molecules 
remained mobile for all 100 ps. Each system was placed in a box in which the layer of the TIP3P water 
molecule was 10 Å. The final systems were neutralized by the addition of Na + and Cl– ions to a 
concentration of 150 mM. All simulations were performed under periodic boundary conditions using the 
V-Rescale Thermostat algorithm to maintain temperature (310 K) and the Parrinello-Rahman Barostat 
algorithm for constant pressure (1 bar) (Bussi et al., 2007; Parrinello and Rahman, 1981). Long-range 
unrelated interactions were calculated using the Particle-Mesh-Ewald (PME) method (Abraham and 
Gready, 2011). All molecules were relaxed with a molecular dynamics simulation of 100 ns. Ligand 
topologies were created using the antechamber module from the AmberTools18 package (Case et al., 
2005). 
 
VIII. DOCKING METHODS 
A. Site Mapping on Proteins 
We used SiteMapper (Bhachoo and Beuming, 2017) to identify possible binding sites for 
docking affinity with the proteins Ace2 (allosteric site), Tmprss2, and Mpro. We also used our novel MDS 
biasing technique algorithm, Maxwell’s demon MD, for searching within these sites for potential flexible 
zones that would have beneficial peptide interactions, which served as a reductive filter limiting the total 
number of possible sites screened on the proteins to those with adequately deep binding grooves 
(Caulfield, 2011; Kayode et al., 2016) or interesting insertion sites (Ace2). 
 
B. Glide Docking 
Prior to the docking with the Ace2 (allosteric site), Tmprss2, and Mpro, we had completed 
rigorous molecular dynamics simulations (MDS) and Monte Carlo (MC) conformational searching for 
each model for additional conformational sampling, using methods previously described in the literature 
(Caulfield and Devkota, 2012; Caulfield, 2011; Caulfield et al., 2011). The primary purpose of MC, in 
this scenario, is examining any conformational variability that may occur with different orientations in 
the region near to protein-protein interfaces. 
Over three million compounds were docked to each site using the Glide XP docking program 
(Bhachoo and Beuming, 2017). All compounds were accounted for using OPLS3 within Maestro 
program (Maestro-9.4, 2014). Using our published docking protocols on each identified site, we 
reductively scanned from 100s to the top 10 poses from each docking and then did cross-comparisons 
of docking scores to retain only the top binding pose of each compound from each site in a winner-
takes-all strategy.  
 
C. Other Docking (positional constraints) 
 Each compound has been converted into a set of energy minimized three-dimensional shapes with the 
Ligprep module. Without protein preparation, it was used for the correct distribution of protonation and 
post-minimization in the OPLS3 force field. In the case of assigning restrictions based on ligands (Mpro, 
Tmprss2), we tried to cover the most important and strong interactions. In the case of Ace2, a set of 
constraints was generated in sufficient quantities to generate combinations of possible interactions. 
Positional constrains (1.8 A radius) and h-bond constraints were generated in the Schrodinger Glide 
module, namely in the mesh generation tool. Aromatic and hydrophobic features were represented with 
short SMARTS. A partial matching protocol for applying constraints has also been used to improve 
process accuracy. A high throughput screening protocol with regulated ligand flexibility was applied. 
 
D. Docking Parameters 
Each compound has been converted into a set of energy minimized three-dimensional shapes 
with the Ligprep module. Without protein preparation, it was used for the correct distribution of 
protonation and post-minimization in the OPLS3 force field. In the case of assigning restrictions based 
on ligands (Mpro, Tmprss2), we tried to cover the most important and strong interactions. In the case of 
Ace2, a set of constraints was generated in sufficient quantities to generate combinations of possible 
interactions. Positional constrains (1.8 A radius) and h-bond constraints were generated in the 
Schrodinger Glide module, namely in the mesh generation tool. Aromatic and hydrophobic features 
were represented with short SMARTS. A partial matching protocol for applying constraints has also 
been used to improve process accuracy. A high throughput screening protocol with regulated ligand 
flexibility was applied. 
Conformations of compound orientations were generated using our standard protocols 
(Bhachoo and Beuming, 2017; Kalid et al., 2012; Unger et al., 2015). The starting conformation of 
relaxed protein structures was first obtained by the method of Polak-Ribière conjugate gradient (PRCG) 
energy minimization with the Optimized Potentials for Liquid Simulations (OPLS) 2005 force field 
(Jorgensen, 2004; Jorgensen and Tiradorives, 1988) for 5000 steps, or until the energy difference 
between subsequent structures was less than 0.001 kJ/mol-Å units. Our docking methodology has 
been described previously (Caulfield and Devkota, 2012; Friesner et al., 2006; Loving et al., 2009; 
Vivoli et al., 2012). 
Briefly, compounds were docked within the Schrödinger software suite (Mohamadi et al., 1990) 
using a virtual screening workflow (VSW) (Bhachoo and Beuming, 2017; Friesner et al., 2006; 
Jacobson et al., 2002; Kalid et al., 2012; Kozakov et al., 2006). Alternative docking methods were also 
employed, including in-house software techniques for top leads for SAR elucidation. The top seeded 
poses were ranked and unfavorable scoring poses were discarded. Top favorable scores from initial 
dockings yielded hundreds of poses with the top five poses retained. Molecular interactions of the 
ligand-protein interfaces were used to help determine the optimal binding set, which included 
descriptors were used to obtain atomic energy terms like hydrogen bond interaction, electrostatic 
interaction, hydrophobic enclosure and π-π stacking interaction that result during the docking run. 
Molecular modeling for importing and refining the proteins was completed (Maestro-9.4, 2014). 
Examinations of structure stability were examined for all proteins investigated, S-protein:Ace2, 
Tmprss2, and Mpro, respectively (Caulfield and Devkota, 2012; Caulfield and Medina-Franco, 2011; 
Caulfield, 2011; Reumers et al., 2005; Schymkowitz et al., 2005; Zhang et al., 2013). Object stability 
was used to determine if any changes in structure that were deleterious to function from immediate 
inspection, which the FoldX algorithm can provide, prior to docking studies. Thus, we examined the 
local residues around the docking site and determined an electrostatic calculation may be useful to 
explain the change in function. The molecular model for the full structure and its truncated form are 
given (Fig. S1) using our state of the art methods, which have been established (Abdul-Hay et al., 
2013; Ando et al., 2017; Caulfield and Devkota, 2012; Caulfield and Medina-Franco, 2011; Caulfield, 
2011; Caulfield et al., 2011; Caulfield et al., 2014; Caulfield et al., 2015; Fiesel et al., 2015a; Fiesel et 
al., 2015b; Puschmann et al., 2017; Zhang et al., 2013). 
Local residues within the 12Å cutoff near docking sites were analyzed (Fig. S1-S2). Any 
interactions requiring inducible fit, or Threonine/Serine hydroxyl rotation or other docking parameter (π-
stacking/halogen-directionality) were also included. Mapping electrostatics was accomplished using the 
Poisson-Boltzmann calculation for solvation on all amino acids for each docked structure (Caulfield and 
Devkota, 2012; Caulfield and Medina-Franco, 2011; Caulfield, 2011; Reumers et al., 2005; 
Schymkowitz et al., 2005; Zhang et al., 2013)  
 
E. Libraries used 
Compounds were derived from either a set of all FDA approved and clinical tested compounds, 
bioactive set of compounds, or a large multi-million compound set from ZINC database. In the all cases 
the libraries were prepared using LigPrep described above. The ZINC database was pruned using 
parameters for better drug-like profile and removal of reactive functional groups and poor 
chemoinformatics properties delivering a large set suitable for screening on all targets across dynamic 
time points from MDS. 
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FIGURE LEGENDS 
Figure 1. Flowchart for drug pipeline for attacking COVID-19 via polypharma small molecule 
approach using in silico screening and advanced simulation biasing. (A) Biological infection of 
SARS-CoV-2 from initial binding, entry and replication for virus proliferation. (B) Overview of COVID-19 
Drug Discovery Pipeline. 
 
Figure 2. Protein-Protein Interaction (PPI) region on the surface of Ace2 identifies key residues. 
(A) PPI region (yellow) on the surface of Ace2 is shown with important residues K353, D155, Y41, K31 
highlighted in yellow. (B) Zoomed in detail panel shows beta sheet secondary structure and H-bond 
interactions targeted for disruption by docked small molecules. 
 
Figure 3. Ace2 protein docked with exemplar ligands during MD simulations and used as basis 
for large-scale constraint-based screening. (A) protein and its final state of MD (B), which differs 
from Y41A mutant due to significant surface changes (C). (D-E) examination of the binding pockets 
change in shape as during MD simulations with the tested ligands bound with key interaction residues 
in red. (G-I) Surfaces removed and zoom into the ligands docked at the site (inserted versus slipping 
out). (J-L) Energy of the ligand lowers system (more stable versus slippage, where no effect observed). 
 
Figure 4. Modeling requires molecular dynamics to reflect optimal inhibitor binding sites. (A-D) 
Ace2:S protein stabilization and effect of ligand binding at allosteric site. (A) Number of hydrogen bonds 
for each ligand with Ace2 against each frame of the simulation. Blue is ligand 300, orange is ligand 392, 
green is ligand 488. (B) RMSD of Ace2 across every frame in the simulation, bound to different ligands. 
(C) RMSF per residue of Ace2 in each MDS bound to different ligands. (D) RMSF heat-mapped onto 
Ace2 and ligand 300. A call-out box shows a close-up of ligand and binding site. Ligand and binding 
site residues represented as sticks with labels and interaction distances. The scale is a BWR gradient 
from 0 to 2.0 Å RMSF. (E-G) Tmprss2 dynamics reveal the catalytically active form suitable for 
inhibition. (E) RMSD in Å across the 25 ns MDS trajectory mapped as a 2D plot. (F) Per residue 
average RMSF in Å across the trajectory mapped as a 2D plot. Disulfide bonds and catalytic triad are 
represented as sticks. The scale is a BWR gradient from 0 to 2.0 Å RMSF. (G) Post-cleavage (mature 
protease) extracellular domain of Tmprss2. Call-out box shows close-up of canonical serine protease 
catalytic triad of mature Tmprss2, with distances of polar contacts. (H_K) Model refinement for Mpro 
reveals ligand binding sites suitable for docking. (H) Average RMSF per residue heat-mapped onto the 
Mpro structure. The scale is a BWR gradient from 0 to 2.0 Å RMSF. (I) RMSD of Mpro for each frame of 
the simulation. (J) Average RMSF per residue of Mpro (each chain measured separately). (K) Mpro 
(orange) with small molecule inhibitor (cyan). 
 
Figure 5. Modelled catalytically active form of Tmprss2 bound to inhibitors. (A) Homology model 
of TMPRSS2 based on crystal structure of thrombin (3F68) is shown docked with 1-(2-Fluoro-5-
methylphenyl)-N-[2-(4-fluorophenyl)-2-hydroxypropyl]-4-hydroxy-1H-pyrazole-3-carboxamide (B). A 
proposed macrocycle-bound structure (C) and docked N-(2-4-[3-(2-Carbamoylphenyl)propanoyl]-1,1-
dioxido-2-thiomorpholinyl}ethyl)-2-oxo-2,3-dihydro-1H-benzimidazole-4-carboxamide (D) as further 
exemplars for inhibition of Tmprss2. 
 
Figure 6. Druggability of Mpro is demonstrated with detailed analysis of α-Keto amide group 
binding using MD simulations. (A) The alignment of two Mpro crystal structures (7BQY/cyan and Mpro-
x0434/purple from diamond.ac.uk) bound to compounds containing an α-Keto amide group flanked by 
hydrophobic groups is shown. Sufficient structural stability of the binding site is demonstrated via 
comparative visualization of initial (B) and final (C) states of MD. Binding site retains its geometry and 
shape across the MD. (D) Two bound states of hit compounds from the large library of compounds give 
further exemplars: Z1609752806 (D) and Z1143050660 (E) in complex with Mpro protein. 
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Table S1. Hydrogen bond occupancy over 15 ns MDS trajectory for each ligand with ACE2. 
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Figure S1: Ace2:S protein interface and indication of allosteric site relative to active binding site. 
(A) Sagittal view of ACE2 (gray) interface with RBD of COVID19 S-protein (green); the blue surface 
highlights the binding site for ligands that disrupt the interface between the two proteins. (B) ACE2 (gray) 
and S-protein (green) sagittal view. In maroon is the active site of ACE2. (C) ACE2 (salmon) with ligand 
300 (blue) rendered as surfaces. 50% left side slab to examine deep insertion in more detail. (D) Full 
surface view of ACE2 and ligand 300. (E) 50% right side slab to examine deep insertion in more detail. 
(F) Example of docked compound that disrupts interface between ACE2 and S-protein. Close-up of 
binding site of ACE2 (salmon) and ligand 300 (blue) with residues and polar contact distances labeled.  
(G) Ligand Interaction Diagram rendered with Maestro for ACE2 with ligand 300 at the 
allosteric site impacting S-protein binding from SAR-CoV2. This 2D "flat" representation shows 
the interactions at this particular compounds interface on Ace2 that would interfere with S 
protein binding. In particular, extending from deeply inserted to superficial, the interactions are 
described in the subsequent sentences. D382 and D350 are hydrogen bond acceptors (side 
chains) from the opposite NH+ on the piperazine-like ring deeply inserted into the binding 
pocket. R393 is a hydrogen bond donor (side chain) to the alcohol group connecting the 
piperazine-like ring to the fused ring. E37 is a hydrogen bond acceptor (side chain) to one of 
the NH on the fused ring. The fluorocyclohexane group is entirely solvent-exposed at the 
mouth of the binding pocket. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S2 Glycosylation sites of Ace2 protein (D616G highlighted red). 
Although glycosylation sites at residues N165, N234, N343 from S-protein (PDB 
code 6VSB), are nearby the ACE2:S-protein binding interface, they do not overlap 
and interfere with the protein-protein interface, offering an adjacent site is readily 
available for PPI docking (S-prot glycosylation analysis: DOI: 
10.1126/science.abb9983; 10.1101/2020.04.29.069054}. The majority of 
glycosylation sites are not on the RBD (Fig. S2), the glycosylation site that is 
actually present on the RBD, N343, is not in 3D proximity to the binding interface. 
Recently, a variant of the S-protein, D614G, was identified to possess enhanced 
transmissibility and resistance to contemporary interventions and this site is not 
present on the RBD. Neither the glycosylation sites, nor the enhanced 
transmissibility variant D614G, are within the 3D proximity to the drug binding site 
for our targeted protein-protein interface disrupting therapeutics for Ace2. 
 
 
 
 
 
Figure S3. Gradually crumbling binding site. (A) Initital and (B) Final states - of the 
protein model, while catalytically active state has better preserved binding site. 
Prothrombin binding site (PDB 3F68) with its inhibitor (C) and the final state of 
Prothrombin (D) are shown. Again, Prothrombin binding site (3F68) with its inhibitor 
(E) and proposed structural model – a prothrombin-based homology model of 
TRPMSS2 (F), which looks more accurate then previous (B) model structure. This 
version maintains structural stability and is good candidate for drug docking with 
ligands. Purple spheres are constraints used to impose good relative positioning. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S4. Proteases cathepsin L and K can be also used in blocking ENTRY of 
COVID-19 during late-endosome progression. Top panel. Structures for cathepsin K 
(PDB code: 4N8W, green) and cathepsin L (PDB code: 2YJB, cyan), shown with an 
inhibitor (blue). The active site residues are colored maroon. These represent additional 
host protease targets at another stage of the viral entry cycle. Bottom panel. Same as top 
but rotated 180°. Cathepsins K and L represent additional host protease targets at another 
stage of the viral entry cycle. Future efforts and alternative methods on our part may involve 
discovering effective compounds to exploit this point of intervention in synergy with our 
other therapeutics. In anticipation of this, we have already constructed models of both of 
these cathepsins, which exhibit remarkable structural homology with each other. For 
cathepsin K, 4N8W.pdb {PMID: 25422423} was used as a base from which to construct the 
model, and 2YJB.pdb {PMID: 21898833} was used for cathepsin L. 
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TABLE S2. Top 310 NCE compounds docked with Ace2, TMRPSS2, and Mpro (from >10million compounds on all targets)
2D	Structure Compound	Name ENZYME Docking	Score Smile
N-[(4-methylmorpholin-2-yl)methyl]-4-[(4-
methylpiperazin-1-yl)methyl]benzamide
ACE2 -7.415595 CN1CCN(Cc2ccc(cc2)C(=O)NCC2CN(C)
CCO2)CC1
2-(3-hydroxypiperidin-1-yl)-N-(4-methyl-3-
sulfamoylphenyl)acetamide
ACE2 -7.377284 Cc1ccc(NC(=O)CN2CCCC(O)C2)cc1S(N)
(=O)=O
2-{4-[(1,3-benzothiazol-2-yl)methyl]piperazin-1-yl}-
N-{4-[(pyrrolidin-1-yl)methyl]phenyl}acetamide
ACE2 -7.733448 O=C(CN1CCN(Cc2nc3ccccc3s2)CC1)Nc
1ccc(CN2CCCC2)cc1
3-({[(2,5-difluorophenyl)methyl]amino}methyl)-N-
methylbenzene-1-sulfonamide
ACE2 -7.527599 CNS(=O)(=O)c1cccc(CNCc2cc(F)ccc2F)
c1
N-methyl-3-({[(3-
nitrophenyl)methyl]amino}methyl)benzene-1-
sulfonamide
ACE2 -7.486144 CNS(=O)(=O)c1cccc(CNCc2cccc(c2)[N+
]([O-])=O)c1
(1S,2R)-1-{[(1H-imidazol-2-yl)methyl]amino}-2,3-
dihydro-1H-inden-2-ol
ACE2 -7.818057 O[C@@H]1Cc2ccccc2[C@@H]1NCc1n
cc[nH]1
1,3-dimethyl-7-({6-methylimidazo[1,2-a]pyridin-2-
yl}methyl)-2,3,6,7-tetrahydro-1H-purine-2,6-dione
ACE2 -7.813326 Cc1ccc2nc(Cn3cnc4n(C)c(=O)n(C)c(=O
)c34)cn2c1
7-({6-chloroimidazo[1,2-a]pyridin-2-yl}methyl)-1,3-
dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione
ACE2 -7.787989 Cn1c2ncn(Cc3cn4cc(Cl)ccc4n3)c2c(=O
)n(C)c1=O
1-[4-({[(thiophen-3-
yl)methyl]amino}methyl)phenyl]piperidine-3-
carboxamide	hydrochloride
ACE2 -7.346939 Cl.NC(=O)C1CCCN(C1)c1ccc(CNCc2ccs
c2)cc1
[3-({[(2,5-
difluorophenyl)methyl]amino}methyl)phenyl]meth
anol
ACE2 -7.273845 OCc1cccc(CNCc2cc(F)ccc2F)c1
1-[4-({[(5-methylfuran-2-
yl)methyl]amino}methyl)phenyl]piperidine-3-
carboxamide	hydrochloride
ACE2 -7.368915 Cl.Cc1ccc(CNCc2ccc(cc2)N2CCCC(C2)C
(N)=O)o1
[(4-cyclopropylmorpholin-2-yl)methyl]({2,6-
dimethylimidazo[2,1-b][1,3]thiazol-5-
yl}methyl)amine
ACE2 -7.838944 Cc1cn2c(CNCC3CN(CCO3)C3CC3)c(C)n
c2s1
N-{2-[2-(4-methylpiperazin-1-
yl)ethoxy]phenyl}thiophene-2-carboxamide
ACE2 -7.649969 CN1CCN(CCOc2ccccc2NC(=O)c2cccs2)
CC1
N-{2-[2-(4-methylpiperazin-1-
yl)ethoxy]phenyl}furan-2-carboxamide
ACE2 -7.32206 CN1CCN(CCOc2ccccc2NC(=O)c2ccco2)
CC1
N-{2-[2-(4-methylpiperazin-1-
yl)ethoxy]phenyl}cyclohex-3-ene-1-carboxamide
ACE2 -7.790159 CN1CCN(CCOc2ccccc2NC(=O)C2CCC=
CC2)CC1
N-{2-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl}-3-
(naphthalen-1-yl)prop-2-enamide
ACE2 -7.25658 CN1CCN(CCOc2ccccc2NC(=O)C=Cc2cc
cc3ccccc23)CC1
1-{[3-({[(2,5-
difluorophenyl)methyl]amino}methyl)phenyl]meth
yl}piperidine-3-carboxamide
ACE2 -7.835397 NC(=O)C1CCCN(Cc2cccc(CNCc3cc(F)cc
c3F)c2)C1
1-(2,4-difluorophenyl)-N-[(1H-imidazol-2-
yl)methyl]pyrrolidin-3-amine
ACE2 -7.890993 Fc1ccc(N2CCC(C2)NCc2ncc[nH]2)c(F)c
1
N-[2-methyl-3-(4-methylpiperazin-1-yl)propyl]-1H-
1,3-benzodiazole-2-carboxamide
ACE2 -7.198821 CC(CNC(=O)c1nc2ccccc2[nH]1)CN1CC
N(C)CC1
2-[(4,5-dimethyl-1H-imidazol-1-yl)methyl]-1-ethyl-
4-fluoro-1H-1,3-benzodiazole
ACE2 -7.938425 CCn1c(Cn2cnc(C)c2C)nc2c(F)cccc12
4-[(2-amino-2,3-dimethylbutyl)amino]-N-methyl-3-
nitrobenzene-1-sulfonamide
ACE2 -7.442683 CNS(=O)(=O)c1ccc(NCC(C)(N)C(C)C)c(c
1)[N+]([O-])=O
1-ethyl-N-{2-fluoro-5-[2-(2-methylpiperidin-1-
yl)acetamido]phenyl}-1H-pyrazole-4-carboxamide
ACE2 -7.589474 CCn1cc(cn1)C(=O)Nc1cc(NC(=O)CN2C
CCCC2C)ccc1F
3-ethyl-1-(2-{4-[(6-methylpyridin-2-
yl)amino]piperidin-1-yl}propanoyl)urea
ACE2 -7.789715 CCNC(=O)NC(=O)C(C)N1CCC(CC1)Nc1
cccc(C)n1
2-(4-chlorophenyl)-2-({3-nitroimidazo[1,2-a]pyridin-
2-yl}amino)acetamide
ACE2 -7.548985 NC(=O)C(Nc1nc2ccccn2c1[N+]([O-
])=O)c1ccc(Cl)cc1
N-{[(2-bromophenyl)carbamoyl]methyl}-2-{4-
[(thiophen-3-yl)methyl]piperazin-1-yl}acetamide
ACE2 -7.056257 Brc1ccccc1NC(=O)CNC(=O)CN1CCN(Cc
2ccsc2)CC1
6-chloro-4-{[(1,4-dimethylpiperazin-2-
yl)methyl]amino}quinoline-3-carbonitrile
ACE2 -7.690945 CN1CCN(C)C(CNc2c(cnc3ccc(Cl)cc23)C
#N)C1
7-[({[1-(difluoromethyl)-1H-imidazol-2-
yl]methyl}(methyl)amino)methyl]-3-methyl-5H-
[1,3]thiazolo[3,2-a]pyrimidin-5-one
ACE2 -7.368598 CN(Cc1nccn1C(F)F)Cc1cc(=O)n2c(C)cs
c2n1
N-(3-cyanophenyl)-2-({imidazo[1,2-a]pyridin-2-
yl}methoxy)benzamide
ACE2 -7.272896 O=C(Nc1cccc(c1)C#N)c1ccccc1OCc1cn
2ccccc2n1
N-[(2-fluorophenyl)methyl]-2-({imidazo[1,2-
a]pyridin-2-yl}methoxy)benzamide
ACE2 -7.504407 Fc1ccccc1CNC(=O)c1ccccc1OCc1cn2cc
ccc2n1
N-(4-fluoro-2-methylphenyl)-2-({imidazo[1,2-
a]pyridin-2-yl}methoxy)benzamide
ACE2 -7.256458 Cc1cc(F)ccc1NC(=O)c1ccccc1OCc1cn2
ccccc2n1
N-(2-carbamoylcyclohexyl)-4-[(4-methylpiperazin-1-
yl)methyl]benzamide
ACE2 -7.2544 CN1CCN(Cc2ccc(cc2)C(=O)NC2CCCCC2
C(N)=O)CC1
3-bromo-5-chloro-2-hydroxy-N-[(1-methyl-1H-
imidazol-2-yl)methyl]benzamide
ACE2 -7.396006 Cn1ccnc1CNC(=O)c1cc(Cl)cc(Br)c1O
3,7-dimethyl-1-[3-(morpholin-4-yl)propyl]-2,3,6,7-
tetrahydro-1H-purine-2,6-dione
ACE2 -7.740514 Cn1cnc2n(C)c(=O)n(CCCN3CCOCC3)c(
=O)c12
2-(4-benzylmorpholin-2-yl)-N-[2-hydroxy-3-(4-
methylpiperazin-1-yl)propyl]-N-methylacetamide
ACE2 -7.062327 CN(CC(O)CN1CCN(C)CC1)C(=O)CC1CN
(Cc2ccccc2)CCO1
N-[3-({[(2-chloro-4-
fluorophenyl)methyl]amino}methyl)phenyl]-2-
(dimethylamino)acetamide
ACE2 -7.794252 CN(C)CC(=O)Nc1cccc(CNCc2ccc(F)cc2
Cl)c1
2-({imidazo[1,2-a]pyridin-2-yl}methoxy)-N-
({[1,2,4]triazolo[4,3-a]pyridin-3-
yl}methyl)benzamide
ACE2 -7.670744 O=C(NCc1nnc2ccccn12)c1ccccc1OCc1
cn2ccccc2n1
2,5-difluoro-4-methyl-N-[(piperidin-3-
yl)methyl]benzamide	hydrochloride
ACE2 -7.244727 Cl.Cc1cc(F)c(cc1F)C(=O)NCC1CCCNC1
2,5-dichloro-N-[(piperidin-3-yl)methyl]benzamide	
hydrochloride
ACE2 -7.847098 Cl.Clc1ccc(Cl)c(c1)C(=O)NCC1CCCNC1
6-chloro-N-[(piperidin-3-yl)methyl]pyridine-2-
carboxamide	hydrochloride
ACE2 -7.817936 Cl.Clc1cccc(n1)C(=O)NCC1CCCNC1
5-chloro-1-methyl-N-[2-(piperidin-3-yl)ethyl]-1H-
imidazole-4-sulfonamide	hydrochloride
ACE2 -7.845325 Cl.Cn1cnc(c1Cl)S(=O)(=O)NCCC1CCCN
C1
N-{2-[2-(dimethylamino)ethyl]-2,3-dihydro-1H-
isoindol-4-yl}-2-(4-hydroxyphenyl)acetamide
ACE2 -7.443014 CN(C)CCN1Cc2cccc(NC(=O)Cc3ccc(O)c
c3)c2C1
1-(4-fluorophenyl)-3-{[(1-methyl-1H-imidazol-2-
yl)methyl]amino}butan-1-ol
ACE2 -7.334131 CC(CC(O)c1ccc(F)cc1)NCc1nccn1C
[1-(1-methyl-1H-imidazol-2-yl)ethyl]({[6-(2-
methylmorpholin-4-yl)pyridin-3-yl]methyl})amine
ACE2 -7.83441 CC(NCc1ccc(nc1)N1CCOC(C)C1)c1nccn
1C
N-[3-({methyl[(1,3-thiazol-4-
yl)methyl]amino}methyl)phenyl]pyrrolidine-2-
carboxamide	hydrochloride
ACE2 -7.740865 Cl.CN(Cc1cscn1)Cc1cccc(NC(=O)C2CC
CN2)c1
5-methyl-2-{[3-(4-methylpiperazin-1-
yl)propyl]sulfanyl}-1H-1,3-benzodiazole
ACE2 -7.876119 CN1CCN(CCCSc2nc3cc(C)ccc3[nH]2)CC
1
{[6-methyl-2-(pyrrolidin-1-yl)pyridin-3-
yl]methyl}[(5-methylfuran-2-yl)methyl]amine
ACE2 -7.84725 Cc1ccc(CNCc2ccc(C)nc2N2CCCC2)o1
N-[3-(1-{[(4-methoxypyridin-2-
yl)methyl]amino}ethyl)phenyl]acetamide
ACE2 -7.566234 COc1ccnc(CNC(C)c2cccc(NC(C)=O)c2)c
1
3-({[(4-cyclopropylmorpholin-2-
yl)methyl]amino}methyl)-N,N-dimethylpyridin-4-
amine
ACE2 -7.891833 CN(C)c1ccncc1CNCC1CN(CCO1)C1CC1
[(1,3-diphenyl-1H-pyrazol-5-yl)carbamoyl]methyl	3-
[(1,1-dioxo-1λ⁶,2-benzothiazol-3-
yl)amino]propanoate
ACE2 -7.414 O=C(COC(=O)CCNC1=NS(=O)(=O)c2cc
ccc12)Nc1cc(nn1-c1ccccc1)-c1ccccc1
2-fluoro-6-hydroxy-N-[2-(1-methyl-1H-imidazol-2-
yl)ethyl]benzamide
ACE2 -7.366927 Cn1ccnc1CCNC(=O)c1c(O)cccc1F
5-{[3-({2-[(dimethylamino)methyl]pyridin-4-
yl}oxy)pyrrolidin-1-yl]methyl}-2,3-dihydro-1H-1,2,4-
triazol-3-one
ACE2 -7.785194 CN(C)Cc1cc(OC2CCN(Cc3nc(=O)[nH][n
H]3)C2)ccn1
2-amino-6-[({1-[3-(4-
fluorophenyl)propanoyl]pyrrolidin-3-
yl}(methyl)amino)methyl]-3,4-dihydropyrimidin-4-
one
ACE2 -7.643808 CN(Cc1cc(=O)[nH]c(N)n1)C1CCN(C1)C
(=O)CCc1ccc(F)cc1
[(3,5-dimethyl-1-phenyl-1H-pyrazol-4-
yl)carbamoyl]methyl	2-({[(4-
fluorophenyl)carbamoyl]methyl}sulfanyl)propanoa
te
ACE2 -7.465323 CC(SCC(=O)Nc1ccc(F)cc1)C(=O)OCC(=
O)Nc1c(C)nn(c1C)-c1ccccc1
[(1-methyl-1H-imidazol-5-yl)methyl]({[2-methyl-4-
(trifluoromethyl)phenyl]methyl})amine
ACE2 -7.915507 Cc1cc(ccc1CNCc1cncn1C)C(F)(F)F
3-[(4-methylpiperazin-1-yl)methyl]-N-[1-(4H-1,2,4-
triazol-3-yl)cyclobutyl]benzamide
ACE2 -7.344405 CN1CCN(Cc2cccc(c2)C(=O)NC2(CCC2)c
2nnc[nH]2)CC1
N-[2-(dimethylamino)-2-phenylethyl]-2-[(5-methyl-
1H-1,3-benzodiazol-2-yl)sulfanyl]acetamide
ACE2 -7.040755 CN(C)C(CNC(=O)CSc1nc2cc(C)ccc2[nH]
1)c1ccccc1
N-[2-(carbamoylmethyl)-1,2,3,4-
tetrahydroisoquinolin-7-yl]-2-oxo-2,3-dihydro-1H-
1,3-benzodiazole-5-carboxamide
ACE2 -7.125758 NC(=O)CN1CCc2ccc(NC(=O)c3ccc4[nH
]c(=O)[nH]c4c3)cc2C1
[(2-bromo-6-fluorophenyl)methyl]({[1-
(difluoromethyl)-1H-imidazol-2-yl]methyl})amine
ACE2 -7.863935 FC(F)n1ccnc1CNCc1c(F)cccc1Br
[1-(5-chloropyridin-2-yl)piperidin-4-yl](1H-imidazol-
2-yl)methanol
ACE2 -7.910061 OC(C1CCN(CC1)c1ccc(Cl)cn1)c1ncc[nH
]1
5-bromo-2-hydroxy-N-[2-
(methylamino)propyl]benzamide
ACE2 -7.621056 CNC(C)CNC(=O)c1cc(Br)ccc1O
6-{1-[(6-methoxy-1,2,3,4-tetrahydronaphthalen-1-
yl)amino]ethyl}-2,3-dihydropyridazin-3-one
ACE2 -7.855813 COc1ccc2C(CCCc2c1)NC(C)c1ccc(=O)[
nH]n1
4-[(pyrrolidin-2-yl)methoxy]benzene-1-
sulfonamide	hydrochloride
ACE2 -7.907147 Cl.NS(=O)(=O)c1ccc(OCC2CCCN2)cc1
N-[1-(1H-imidazol-1-yl)propan-2-yl]-1-(piperidin-3-
yl)-1H-pyrazole-3-carboxamide
ACE2 -7.895666 CC(Cn1ccnc1)NC(=O)c1ccn(n1)C1CCC
NC1
methyl({[1-(1,2,3,4-tetrahydroisoquinoline-3-
carbonyl)piperidin-3-yl]methyl})amine
ACE2 -7.078639 CNCC1CCCN(C1)C(=O)C1Cc2ccccc2CN
1
N-[2-hydroxy-2-(2-methoxyphenyl)ethyl]piperidine-
2-carboxamide
ACE2 -7.278091 COc1ccccc1C(O)CNC(=O)C1CCCCN1
N-[2-(4-chlorophenyl)-2-hydroxyethyl]morpholine-
3-carboxamide
ACE2 -7.905742 OC(CNC(=O)C1COCCN1)c1ccc(Cl)cc1
3-{[3-({2-[(dimethylamino)methyl]pyridin-4-
yl}oxy)pyrrolidin-1-yl]methyl}pyridin-2-amine
ACE2 -7.520437 CN(C)Cc1cc(OC2CCN(Cc3cccnc3N)C2)c
cn1
N-({thieno[3,2-b]thiophen-2-yl}methyl)-5H,6H,7H-
pyrrolo[1,2-a]imidazol-7-amine
ACE2 -7.928268 C(NC1CCn2ccnc12)c1cc2sccc2s1
3-{[6-(4-methylpiperazin-1-yl)pyridin-3-yl]methyl}-
1-[(pyridin-2-yl)methyl]urea
ACE2 -7.875927 CN1CCN(CC1)c1ccc(CNC(=O)NCc2cccc
n2)cn1
1,3-dimethyl-7-(2-methylpropyl)-8-[(piperidin-1-
yl)methyl]-2,3,6,7-tetrahydro-1H-purine-2,6-dione
ACE2 -7.933447 CC(C)Cn1c(CN2CCCCC2)nc2n(C)c(=O)n
(C)c(=O)c12
(4-amino-1,1-difluorobutan-2-yl)({[1-cyclopentyl-3-
(pyridin-2-yl)-1H-pyrazol-4-yl]methyl})amine
ACE2 -7.875737 NCCC(NCc1cn(nc1-
c1ccccn1)C1CCCC1)C(F)F
4-methoxy-N-{2-[2-(piperazin-1-
yl)ethoxy]phenyl}azepane-1-carboxamide
ACE2 -7.309969 COC1CCCN(CC1)C(=O)Nc1ccccc1OCCN
1CCNCC1
3-chloro-6-{[(1,4-oxazepan-2-
yl)methyl]amino}pyridine-2-carbonitrile
ACE2 -7.860086 Clc1ccc(NCC2CNCCCO2)nc1C#N
3-chloro-2-fluoro-4-methyl-N-[(1,4-oxazepan-2-
yl)methyl]benzamide
ACE2 -7.936678 Cc1ccc(C(=O)NCC2CNCCCO2)c(F)c1Cl
({1-[1-(4-fluorophenyl)-1H-imidazole-5-
carbonyl]pyrrolidin-3-yl}methyl)(methyl)amine
ACE2 -7.931379 CNCC1CCN(C1)C(=O)c1cncn1-
c1ccc(F)cc1
2-(4-benzyl-1,4-diazepan-1-yl)-N-{[(4-
fluorophenyl)carbamoyl]methyl}acetamide
ACE2 -7.271333 Fc1ccc(NC(=O)CNC(=O)CN2CCCN(Cc3c
cccc3)CC2)cc1
3-methyl-7-[2-methyl-3-(pyrimidin-2-
ylsulfanyl)propyl]-8-(4-methylpiperazin-1-yl)-
2,3,6,7-tetrahydro-1H-purine-2,6-dione
ACE2 -7.751422 CC(CSc1ncccn1)Cn1c(nc2n(C)c(=O)[nH
]c(=O)c12)N1CCN(C)CC1
1,3-dimethyl-8-[(4-methylpiperazin-1-yl)methyl]-7-
(2-methylpropyl)-2,3,6,7-tetrahydro-1H-purine-2,6-
dione
ACE2 -7.931598 CC(C)Cn1c(CN2CCN(C)CC2)nc2n(C)c(=
O)n(C)c(=O)c12
3-methyl-8-(piperazin-1-yl)-7-(prop-2-en-1-yl)-
2,3,6,7-tetrahydro-1H-purine-2,6-dione
ACE2 -7.460227 Cn1c2nc(N3CCNCC3)n(CC=C)c2c(=O)[
nH]c1=O
3-methyl-7-(2-methylprop-2-en-1-yl)-8-(piperazin-
1-yl)-2,3,6,7-tetrahydro-1H-purine-2,6-dione
ACE2 -7.33643 CC(=C)Cn1c(nc2n(C)c(=O)[nH]c(=O)c1
2)N1CCNCC1
1-methyl-8-[2-(morpholin-4-yl)ethyl]-
1H,2H,3H,4H,6H,7H,8H-imidazo[1,2-g]purine-2,4-
dione
ACE2 -7.330341 Cn1c2nc3N(CCN4CCOCC4)CCn3c2c(=
O)[nH]c1=O
rac-1-[(1R,2R)-2-aminocyclohexyl]-3-{imidazo[1,2-
a]pyridin-7-yl}urea
ACE2 -7.3361
N-(benzyloxy)-2-({imidazo[1,2-a]pyridin-2-
yl}methoxy)benzamide
ACE2 -7.671655 O=C(NOCc1ccccc1)c1ccccc1OCc1cn2c
cccc2n1
2-methoxy-5-(pyrrolidine-2-amido)pyridine-3-
carboxamide
ACE2 -7.783586 COc1ncc(NC(=O)C2CCCN2)cc1C(N)=O
5-bromo-N-[(piperidin-3-yl)methyl]-1H-indazole-3-
carboxamide
ACE2 -7.822889 Brc1ccc2[nH]nc(C(=O)NCC3CCCNC3)c
2c1
N-[(piperidin-3-yl)methyl]-1H-indazole-3-
carboxamide
ACE2 -7.917339 O=C(NCC1CCCNC1)c1n[nH]c2ccccc12
2-(furan-2-yl)-N4-[(pyrrolidin-2-
yl)methyl]imidazo[1,5-a]pyrimidine-4,8-
dicarboxamide
ACE2 -7.250268 NC(=O)c1ncn2c(cc(nc12)-
c1ccco1)C(=O)NCC1CCCN1
N4-(3-amino-4-methylpentyl)-2-(furan-2-yl)-N4-
methylimidazo[1,5-a]pyrimidine-4,8-
dicarboxamide
ACE2 -7.521512 CC(C)C(N)CCN(C)C(=O)c1cc(nc2c(ncn1
2)C(N)=O)-c1ccco1
N-(4,4-difluoropiperidin-3-yl)-5-
(methylsulfamoyl)furan-3-carboxamide
ACE2 -7.306415 CNS(=O)(=O)c1cc(co1)C(=O)NC1CNCC
C1(F)F
2-({3-[2-(azepan-1-
yl)acetamido]phenyl}carbamoyl)-2-methylacetic	
acid
ACE2 -7.696227 CC(C(O)=O)C(=O)Nc1cccc(NC(=O)CN2
CCCCCC2)c1
N-(4,4-difluoropiperidin-3-yl)-5-methyl-4-
sulfamoylfuran-2-carboxamide
ACE2 -7.550276 Cc1oc(cc1S(N)(=O)=O)C(=O)NC1CNCC
C1(F)F
3-methyl-7-{2-methyl-3-[(1-phenyl-1H-1,2,3,4-
tetrazol-5-yl)sulfanyl]propyl}-8-(4-methylpiperazin-
1-yl)-2,3,6,7-tetrahydro-1H-purine-2,6-dione
ACE2 -7.596339
CC(CSc1nnnn1-
c1ccccc1)Cn1c(nc2n(C)c(=O)[nH]c(=O)
c12)N1CCN(C)CC1
1-(3-methylpiperazin-1-yl)-2-[2-(4H-1,2,4-triazol-3-
yl)-1,3-thiazol-4-yl]ethan-1-one
ACE2 -7.906252 CC1CN(CCN1)C(=O)Cc1csc(n1)-
c1nnc[nH]1
4-{[2-(4-methylpiperazin-1-
yl)propyl]amino}quinoline-3-carboxylic	acid
ACE2 -7.251865 CC(CNc1c(cnc2ccccc12)C(O)=O)N1CC
N(C)CC1
6-{3-[(3R)-3-hydroxypyrrolidin-1-yl]azetidine-1-
carbonyl}pyridine-2-carboxamide
ACE2 -7.815683 NC(=O)c1cccc(n1)C(=O)N1CC(C1)N1C
C[C@@H](O)C1
2-{2-[(dimethylamino)methyl]morpholin-4-yl}-1,8-
naphthyridine-3-carbonitrile
ACE2 -7.596166 CN(C)CC1CN(CCO1)c1nc2ncccc2cc1C#
N
2-[3-butyl-8-(hydroxymethyl)-2,6-dioxo-7-propyl-
2,3,6,7-tetrahydro-1H-purin-1-yl]-N-[4-
(trifluoromethyl)phenyl]acetamide
ACE2 -7.861967 CCCCn1c2nc(CO)n(CCC)c2c(=O)n(CC(=
O)Nc2ccc(cc2)C(F)(F)F)c1=O
rac-1-{[(2R,3R)-4-ethyl-3-phenylmorpholin-2-
yl]methyl}-3-{imidazo[1,2-a]pyridin-6-yl}urea
ACE2 -7.339682
2-[(1,2-dimethyl-1H-imidazol-5-yl)methyl]-5,8-
dimethoxy-1,2,3,4-tetrahydroisoquinolin-4-ol
ACE2 -7.821377 COc1ccc(OC)c2C(O)CN(Cc3cnc(C)n3C)
Cc12
N-[1-(piperidin-2-yl)ethyl]pyridine-2-carboxamide ACE2 -7.85541 CC(NC(=O)c1ccccn1)C1CCCCN1
6-({3a-amino-octahydrocyclopenta[c]pyrrol-2-
yl}methyl)pyridazin-3-amine
ACE2 -7.279934 Nc1ccc(CN2CC3CCCC3(N)C2)nn1
N-(2-aminopropoxy)-3-(2,6-difluorophenyl)prop-2-
enamide
ACE2 -7.900215 CC(N)CONC(=O)C=Cc1c(F)cccc1F
N-ethyl-6-(1-methylpiperazine-2-amido)-2,3-
dihydro-1H-indole-1-carboxamide
ACE2 -7.505628 CCNC(=O)N1CCc2ccc(NC(=O)C3CNCC
N3C)cc12
[(2-chloro-1-benzofuran-3-yl)methyl](1,3-
diaminopropan-2-yl)amine
ACE2 -7.91669 NCC(CN)NCc1c(Cl)oc2ccccc12
N-{2-[(4-fluorophenyl)methyl]-1H-1,3-benzodiazol-
5-yl}-2-(4-methylpiperazin-1-yl)acetamide
ACE2 -7.82796 CN1CCN(CC(=O)Nc2ccc3[nH]c(Cc4ccc(
F)cc4)nc3c2)CC1
rac-(3R,4S)-1-[(3-cyclopentyl-1,2,4-oxadiazol-5-
yl)methyl]-4-(1-methyl-1H-imidazol-5-yl)pyrrolidin-
3-amine
ACE2 -7.82452
N-{[6-(3-aminopyrrolidin-1-yl)pyridin-2-yl]methyl}-
1H-pyrazole-5-carboxamide
ACE2 -7.821383 NC1CCN(C1)c1cccc(CNC(=O)c2ccn[nH]
2)n1
7-methyl-N-[(3S,4R)-1-methyl-4-(1-methyl-1H-
imidazol-5-yl)pyrrolidin-3-yl]imidazo[1,5-a]pyridine-
1-carboxamide
ACE2 -7.856272 CN1C[C@@H](NC(=O)c2ncn3ccc(C)cc
23)[C@@H](C1)c1cncn1C
N-[(3S,4R)-1-methyl-4-(1-methyl-1H-imidazol-5-
yl)pyrrolidin-3-yl]-3H-imidazo[4,5-b]pyridine-5-
carboxamide
ACE2 -7.71168 CN1C[C@@H](NC(=O)c2ccc3nc[nH]c3
n2)[C@@H](C1)c1cncn1C
N-(piperidin-3-yl)methanesulfonamide ACE2 -7.829874 CS(=O)(=O)NC1CCCNC1
3-{[(1,5-dimethyl-1H-1,3-benzodiazol-2-
yl)methyl]amino}-1,1-difluoro-2-methylpropan-2-ol
ACE2 -7.784154 Cc1ccc2n(C)c(CNCC(C)(O)C(F)F)nc2c1
({imidazo[1,2-a]pyridin-8-yl}methyl)({[4-(propan-2-
yloxy)phenyl]methyl})amine
ACE2 -7.797499 CC(C)Oc1ccc(CNCc2cccn3ccnc23)cc1
N-{2-[(dimethylamino)methyl]-1H-1,3-benzodiazol-
6-yl}-1-methyl-1H-pyrazole-5-sulfonamide
ACE2 -7.921568 CN(C)Cc1nc2ccc(NS(=O)(=O)c3ccnn3C
)cc2[nH]1
N-[3-(1-{[(5-methylfuran-2-
yl)methyl]amino}ethyl)phenyl]acetamide
ACE2 -7.57716 CC(NCc1ccc(C)o1)c1cccc(NC(C)=O)c1
2-methyl-N-[(1-propyl-1H-imidazol-5-yl)methyl]-
1,2,3,4-tetrahydroisoquinolin-4-amine
ACE2 -7.915427 CCCn1cncc1CNC1CN(C)Cc2ccccc12
N-[3-({[(5-chlorothiophen-2-
yl)methyl]amino}methyl)phenyl]-2-
methoxyacetamide
ACE2 -7.445454 COCC(=O)Nc1cccc(CNCc2ccc(Cl)s2)c1
2-{imidazo[1,2-a]pyridin-2-yl}-N-{[6-(1H-imidazol-1-
yl)pyridin-3-yl]methyl}acetamide
ACE2 -7.33799 O=C(Cc1cn2ccccc2n1)NCc1ccc(nc1)-
n1ccnc1
4-(1H-1,3-benzodiazol-2-yl)-N-[2-(1,2,3,4-
tetrahydroisoquinolin-2-yl)ethyl]butanamide
ACE2 -7.425942 O=C(CCCc1nc2ccccc2[nH]1)NCCN1CCc
2ccccc2C1
4-(1H-1,3-benzodiazol-2-yl)-N-[2-(dimethylamino)-
2-(4-ethylphenyl)ethyl]butanamide
ACE2 -7.538094 CCc1ccc(cc1)C(CNC(=O)CCCc1nc2cccc
c2[nH]1)N(C)C
2-chloro-N-[3-(4-ethylpiperazin-1-yl)propyl]-6-
fluorobenzamide
ACE2 -7.878207 CCN1CCN(CCCNC(=O)c2c(F)cccc2Cl)CC
1
2-{[(2-{imidazo[1,2-a]pyridin-2-
yl}ethyl)carbamoyl]amino}-2-phenylacetamide
ACE2 -7.495692 NC(=O)C(NC(=O)NCCc1cn2ccccc2n1)c
1ccccc1
N-{[2-(4-methylpiperazin-1-yl)pyridin-4-yl]methyl}-
2-(2-oxo-1,3-thiazolidin-3-yl)acetamide
ACE2 -7.935508 CN1CCN(CC1)c1cc(CNC(=O)CN2CCSC2
=O)ccn1
3-(2-{imidazo[1,2-a]pyridin-2-yl}ethyl)-1-[2-
(morpholin-4-yl)propyl]urea
ACE2 -7.478851 CC(CNC(=O)NCCc1cn2ccccc2n1)N1CC
OCC1
N-(2-ethoxyphenyl)-2-[({imidazo[1,2-a]pyridin-2-
yl}methyl)amino]-2-phenylacetamide
ACE2 -7.382268 CCOc1ccccc1NC(=O)C(NCc1cn2ccccc2
n1)c1ccccc1
6,7-dimethoxy-2-[(4-methylpiperazin-1-yl)methyl]-
3,4-dihydroquinazolin-4-one
ACE2 -7.85665 COc1cc2nc(CN3CCN(C)CC3)[nH]c(=O)c
2cc1OC
1-{[(2-oxo-2,3-dihydro-1H-1,3-benzodiazol-5-
yl)carbamoyl]methyl}piperidine-4-carboxamide
ACE2 -7.011648 NC(=O)C1CCN(CC(=O)Nc2ccc3[nH]c(=
O)[nH]c3c2)CC1
2-({[(5-chloro-2-
methoxyphenyl)carbamoyl]methyl}(methyl)amino)-
N-(2-oxo-2,3-dihydro-1H-1,3-benzodiazol-5-
yl)acetamide
ACE2 -7.666898 COc1ccc(Cl)cc1NC(=O)CN(C)CC(=O)Nc
1ccc2[nH]c(=O)[nH]c2c1
2-(decahydroisoquinolin-2-yl)-N-(2-oxo-2,3-dihydro-
1H-1,3-benzodiazol-5-yl)acetamide
ACE2 -7.392527 O=C(CN1CCC2CCCCC2C1)Nc1ccc2[nH]
c(=O)[nH]c2c1
3-(furan-2-carbonyl)-1-[6-({[(furan-2-
yl)formamido]methanethioyl}amino)pyridin-2-
yl]thiourea
ACE2 -7.848658 O=C(NC(=S)Nc1cccc(NC(=S)NC(=O)c2c
cco2)n1)c1ccco1
5-chloro-7-[(4-methylpiperazin-1-
yl)methyl]quinolin-8-ol
ACE2 -7.666059 CN1CCN(Cc2cc(Cl)c3cccnc3c2O)CC1
N-[(4-methylpiperazin-1-yl)methyl]pyrazine-2-
carboxamide
ACE2 -7.566398 CN1CCN(CNC(=O)c2cnccn2)CC1
5-ethoxy-1,3-bis[(3-hydroxypiperidin-1-yl)methyl]-
2,3-dihydro-1H-1,3-benzodiazole-2-thione
ACE2 -7.6796 CCOc1ccc2n(CN3CCCC(O)C3)c(=S)n(C
N3CCCC(O)C3)c2c1
6-[({6-chloroimidazo[1,2-a]pyridin-2-
yl}methyl)sulfanyl]-2,3,4,5-tetrahydro-1,2,4-
triazine-3,5-dione
ACE2 -7.577509 Clc1ccc2nc(CSc3n[nH]c(=O)[nH]c3=O)
cn2c1
13-{[2-(dimethylamino)ethyl]amino}-11-methyl-12-
(3-methylbutyl)-1,8-diazatricyclo[7.4.0.0²,⁷]trideca-
2,4,6,8,10,12-hexaene-10-carbonitrile
ACE2 -7.305675 CC(C)CCc1c(C)c(C#N)c2nc3ccccc3n2c1
NCCN(C)C
16-{[2-(diethylamino)ethyl]amino}-1,8-
diazatetracyclo[7.7.0.0²,⁷.0¹¹,¹⁵]hexadeca-
2,4,6,8,10,15-hexaene-10-carbonitrile
ACE2 -7.363593 CCN(CC)CCNc1c2CCCc2c(C#N)c2nc3cc
ccc3n12
N-[3-({[(2,5-
difluorophenyl)methyl]amino}methyl)phenyl]-2-
methylpropanamide
ACE2 -7.412559 CC(C)C(=O)Nc1cccc(CNCc2cc(F)ccc2F)
c1
[(2,5-difluorophenyl)methyl]({[6-(2,6-
dimethylmorpholin-4-yl)pyridin-3-yl]methyl})amine
ACE2 -7.830545 CC1CN(CC(C)O1)c1ccc(CNCc2cc(F)ccc
2F)cn1
N-[3-({[(3-
methylphenyl)methyl]amino}methyl)phenyl]-3-
(morpholin-4-yl)propanamide
ACE2 -7.438191 Cc1cccc(CNCc2cccc(NC(=O)CCN3CCOC
C3)c2)c1
3-{[({2-[(2,6-dimethylmorpholin-4-
yl)methyl]phenyl}methyl)amino]methyl}benzonitril
e
ACE2 -7.301904 CC1CN(Cc2ccccc2CNCc2cccc(c2)C#N)C
C(C)O1
2-{[(4-methoxyphenyl)(phenyl)methyl]amino}-N-(2-
oxo-2,3-dihydro-1H-1,3-benzodiazol-5-
yl)acetamide
ACE2 -7.302589 COc1ccc(cc1)C(NCC(=O)Nc1ccc2[nH]c(
=O)[nH]c2c1)c1ccccc1
1-[4-({[(3-
fluorophenyl)methyl]amino}methyl)phenyl]piperidi
ne-3-carboxamide
ACE2 -7.795565 NC(=O)C1CCCN(C1)c1ccc(CNCc2cccc(F
)c2)cc1
1-[4-({[(thiophen-2-
yl)methyl]amino}methyl)phenyl]piperidine-3-
carboxamide
ACE2 -7.26034 NC(=O)C1CCCN(C1)c1ccc(CNCc2cccs2)
cc1
1-[4-({[(3-
cyanophenyl)methyl]amino}methyl)phenyl]piperidi
ne-3-carboxamide
ACE2 -7.247289 NC(=O)C1CCCN(C1)c1ccc(CNCc2cccc(c
2)C#N)cc1
2-({2-[({imidazo[1,2-a]pyridin-2-
yl}methyl)sulfanyl]phenyl}formamido)propanamid
e
ACE2 -7.695058 CC(NC(=O)c1ccccc1SCc1cn2ccccc2n1)
C(N)=O
2-[({imidazo[1,2-a]pyridin-2-yl}methyl)sulfanyl]-N-
(1,3,4-thiadiazol-2-yl)benzamide
ACE2 -7.843258 O=C(Nc1nncs1)c1ccccc1SCc1cn2ccccc
2n1
N-({6-chloroimidazo[1,2-a]pyridin-2-yl}methyl)-4-
[(4-methylpiperazin-1-yl)methyl]benzamide
ACE2 -7.623186 CN1CCN(Cc2ccc(cc2)C(=O)NCc2cn3cc(
Cl)ccc3n2)CC1
8-[(4-acetylpiperazin-1-yl)methyl]-3,7-dimethyl-
2,3,6,7-tetrahydro-1H-purine-2,6-dione
ACE2 -7.252306 CC(=O)N1CCN(Cc2nc3n(C)c(=O)[nH]c(
=O)c3n2C)CC1
5-chloro-2-methoxy-N-{2-[(morpholin-4-yl)methyl]-
1H-1,3-benzodiazol-6-yl}benzamide
ACE2 -7.268946 COc1ccc(Cl)cc1C(=O)Nc1ccc2nc(CN3C
COCC3)[nH]c2c1
2-hydroxy-5-methoxy-N-[(morpholin-2-
yl)methyl]benzamide
ACE2 -7.411243 COc1ccc(O)c(c1)C(=O)NCC1CNCCO1
N-[5-(ethanesulfonyl)-2-hydroxyphenyl]-2-
{imidazo[2,1-b][1,3]thiazol-6-yl}acetamide
ACE2 -7.304225 CCS(=O)(=O)c1ccc(O)c(NC(=O)Cc2cn3c
csc3n2)c1
2-({6-chloroimidazo[1,2-a]pyridin-2-yl}methyl)-1,2-
dihydrophthalazin-1-one
ACE2 -7.361447 Clc1ccc2nc(Cn3ncc4ccccc4c3=O)cn2c
1
6-hydroxy-N-{2-[(morpholin-4-yl)methyl]-1H-1,3-
benzodiazol-6-yl}pyridine-3-carboxamide
ACE2 -7.398419 Oc1ccc(cn1)C(=O)Nc1ccc2nc(CN3CCO
CC3)[nH]c2c1
4-acetyl-N-{2-[(morpholin-4-yl)methyl]-1H-1,3-
benzodiazol-6-yl}-1H-pyrrole-2-carboxamide
ACE2 -7.627306 CC(=O)c1c[nH]c(c1)C(=O)Nc1ccc2nc(C
N3CCOCC3)[nH]c2c1
6-{[4-(2,2-difluoroethyl)piperazin-1-yl]methyl}-1-
methyl-1H,4H,5H-pyrazolo[3,4-d]pyrimidin-4-one
ACE2 -7.78928 Cn1ncc2c1nc(CN1CCN(CC(F)F)CC1)[n
H]c2=O
N-{[4-(1H-1,3-benzodiazol-1-yl)phenyl]methyl}-2-
(1H-imidazol-1-yl)propanamide
ACE2 -7.800908 CC(C(=O)NCc1ccc(cc1)-
n1cnc2ccccc12)n1ccnc1
N-[(1-ethylpiperidin-4-yl)methyl]-2-{imidazo[2,1-
b][1,3]thiazol-6-yl}acetamide
ACE2 -7.597419 CCN1CCC(CNC(=O)Cc2cn3ccsc3n2)CC
1
N-({1-[(1-phenyl-1H-1,2,3,4-tetrazol-5-
yl)methyl]pyrrolidin-3-yl}methyl)pyridin-2-amine
ACE2 -7.576307 C(Nc1ccccn1)C1CCN(Cc2nnnn2-
c2ccccc2)C1
1-(2,5-difluorophenyl)-2-{5H,6H,7H,8H-imidazo[1,2-
a]pyrazin-7-yl}ethan-1-ol
ACE2 -7.881457 OC(CN1CCn2ccnc2C1)c1cc(F)ccc1F
3-(furan-2-yl)-5-({5H,6H,7H,8H-imidazo[1,2-
a]pyrazin-7-yl}methyl)-1,2,4-oxadiazole
ACE2 -7.871089 C(N1CCn2ccnc2C1)c1nc(no1)-c1ccco1
1-{5H,6H,7H,8H-imidazo[1,2-a]pyrazin-7-yl}-3-(4-
methylphenoxy)propan-2-ol
ACE2 -7.796023 Cc1ccc(OCC(O)CN2CCn3ccnc3C2)cc1
2-(1-{5H,6H,7H,8H-imidazo[1,2-a]pyrazin-7-
yl}ethyl)-5,6-dimethyl-3H,4H-thieno[2,3-
d]pyrimidin-4-one
ACE2 -7.890335 CC(N1CCn2ccnc2C1)c1nc2sc(C)c(C)c2c
(=O)[nH]1
1-{5H,6H,7H,8H-imidazo[1,2-a]pyrazin-7-yl}-3-
(naphthalen-1-yloxy)propan-2-ol
ACE2 -7.909158 OC(COc1cccc2ccccc12)CN1CCn2ccnc2
C1
2-(1-{5H,6H,7H,8H-imidazo[1,2-a]pyrazin-7-
yl}ethyl)-5-(thiophen-2-yl)-1,3,4-oxadiazole
ACE2 -7.595696 CC(N1CCn2ccnc2C1)c1nnc(o1)-
c1cccs1
2-(furan-2-yl)-5-({5H,6H,7H,8H-imidazo[1,2-
a]pyrazin-7-yl}methyl)-1,3,4-oxadiazole
ACE2 -7.402563 C(N1CCn2ccnc2C1)c1nnc(o1)-c1ccco1
2-(3-{5H,6H,7H,8H-imidazo[1,2-a]pyrazin-7-
yl}propyl)-1,3-benzoxazole
ACE2 -7.644226 C(CN1CCn2ccnc2C1)Cc1nc2ccccc2o1
1-(2,3-dihydro-1H-indol-1-yl)-3-{5H,6H,7H,8H-
imidazo[1,2-a]pyrazin-7-yl}propan-1-one
ACE2 -7.778121 O=C(CCN1CCn2ccnc2C1)N1CCc2ccccc
12
N-[3-(1H-1,3-benzodiazol-1-yl)propyl]-3-methyl-2-
(naphthalene-2-sulfonamido)butanamide
MPRO -7.638746 CC(C)C(NS(=O)(=O)c1ccc2ccccc2c1)C(
=O)NCCCn1cnc2ccccc12
4-methoxy-N-[3-(2-oxopyrrolidin-1-yl)phenyl]-3-{[2-
(pyridin-2-yl)ethyl]sulfamoyl}benzamide
MPRO -7.644347 COc1ccc(cc1S(=O)(=O)NCCc1ccccn1)C(
=O)Nc1cccc(c1)N1CCCC1=O
4-[(3-benzyl-7-butyl-2,6-dioxo-2,3,6,7-tetrahydro-
1H-purin-8-yl)methyl]-3,4-dihydro-2H-1,4-
benzoxazine-2-carboxamide
MPRO -7.759647 CCCCn1c(CN2CC(Oc3ccccc23)C(N)=O)
nc2n(Cc3ccccc3)c(=O)[nH]c(=O)c12
2-[2-(4-ethoxyphenyl)pyrrolidin-1-yl]-N-(3-
sulfamoylphenyl)acetamide
MPRO -7.748233 CCOc1ccc(cc1)C1CCCN1CC(=O)Nc1ccc
c(c1)S(N)(=O)=O
4-[2-(4-cyanophenoxy)acetyl]-N-methyl-3,4-
dihydro-2H-1,4-benzoxazine-2-carboxamide
MPRO -7.673447 CNC(=O)C1CN(C(=O)COc2ccc(cc2)C#N
)c2ccccc2O1
4-[({[phenyl(pyridin-3-
yl)methyl]carbamoyl}amino)methyl]benzamide
MPRO -7.749195 NC(=O)c1ccc(CNC(=O)NC(c2ccccc2)c2
cccnc2)cc1
N-[4-(2-{[(2,3-dihydro-1H-inden-1-
yl)carbamoyl]amino}ethyl)phenyl]acetamide
MPRO -7.640749 CC(=O)Nc1ccc(CCNC(=O)NC2CCc3cccc
c23)cc1
2-{imidazo[1,5-a]pyridin-3-ylsulfanyl}-N-(2-oxo-2,3-
dihydro-1H-1,3-benzodiazol-5-yl)propanamide
MPRO -7.711375 CC(Sc1ncc2ccccn12)C(=O)Nc1ccc2[nH
]c(=O)[nH]c2c1
N-(3-methanesulfinylphenyl)-2-[3-(trifluoromethyl)-
1H-pyrazol-1-yl]acetamide
MPRO -7.618535 CS(=O)c1cccc(NC(=O)Cn2ccc(n2)C(F)(F
)F)c1
N-[(1-benzyl-3,5-dimethyl-1H-pyrazol-4-yl)methyl]-
3-{[(furan-2-yl)methyl]sulfamoyl}benzamide
MPRO -7.646959 Cc1nn(Cc2ccccc2)c(C)c1CNC(=O)c1ccc
c(c1)S(=O)(=O)NCc1ccco1
1-[1-(2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)ethyl]-
3-[2-oxo-1-(propan-2-yl)pyrrolidin-3-yl]urea
MPRO -7.6444 CC(C)N1CCC(NC(=O)NC(C)c2ccc3NC(=
O)CCc3c2)C1=O
2-{[(3-chlorophenyl)methyl](methyl)amino}-N-(2-
oxo-2,3-dihydro-1H-1,3-benzodiazol-5-
yl)propanamide
MPRO -7.705485 CC(N(C)Cc1cccc(Cl)c1)C(=O)Nc1ccc2[n
H]c(=O)[nH]c2c1
2-{[1-(4-ethylphenyl)-2-methylpropyl]amino}-N-(2-
oxo-2,3-dihydro-1H-1,3-benzodiazol-5-
yl)propanamide
MPRO -7.654702 CCc1ccc(cc1)C(NC(C)C(=O)Nc1ccc2[nH
]c(=O)[nH]c2c1)C(C)C
1-tert-butyl-N-(3-carbamoyl-4-fluorophenyl)-3-(2-
ethoxyphenyl)-1H-pyrazole-4-carboxamide
MPRO -7.656709
CCOc1ccccc1-
c1nn(cc1C(=O)Nc1ccc(F)c(c1)C(N)=O)
C(C)(C)C
2-[(2-{2-[2-(4-methoxyphenyl)azepan-1-
yl]acetamido}phenyl)sulfanyl]acetamide
MPRO -7.739322 COc1ccc(cc1)C1CCCCCN1CC(=O)Nc1cc
ccc1SCC(N)=O
N-[2-(3-chlorophenyl)-2-methoxyethyl]-2-oxo-2,3-
dihydro-1H-1,3-benzodiazole-5-carboxamide
MPRO -7.666192 COC(CNC(=O)c1ccc2[nH]c(=O)[nH]c2c
1)c1cccc(Cl)c1
N-[3-(pyrrolidine-1-carbonyl)phenyl]-3-(1H-1,2,4-
triazol-1-yl)piperidine-1-carboxamide
MPRO -7.708583 O=C(Nc1cccc(c1)C(=O)N1CCCC1)N1CC
CC(C1)n1cncn1
1-benzyl-3-hydroxy-N-[(3-hydroxy-5,6-
dimethylpyridazin-4-yl)methyl]pyrrolidine-3-
carboxamide
MPRO -7.768783 Cc1nnc(O)c(CNC(=O)C2(O)CCN(Cc3ccc
cc3)C2)c1C
3-cyclohexyl-3-[2-(3-methyl-2,4-dioxo-1,2,3,4-
tetrahydropyrimidin-1-yl)acetamido]propanamide
MPRO -7.651972 Cn1c(=O)ccn(CC(=O)NC(CC(N)=O)C2C
CCCC2)c1=O
N-({2',3'-dihydrospiro[cyclopropane-1,1'-inden]-3-
yl}methyl)-2-{1H-pyrrolo[2,3-b]pyridin-3-
yl}acetamide
MPRO -7.679692 O=C(Cc1c[nH]c2ncccc12)NCC1CC11CC
c2ccccc12
1-(2-{1-methyl-4-oxo-1H,4H,5H-pyrazolo[3,4-
d]pyrimidin-5-yl}acetyl)-octahydro-1H-indole-2-
carboxylic	acid
MPRO -7.705968 Cn1ncc2c1ncn(CC(=O)N1C3CCCCC3CC
1C(O)=O)c2=O
4-{[2-(6-fluoro-1H-indol-3-yl)-N-
methylacetamido]methyl}benzoic	acid
MPRO -7.737004 CN(Cc1ccc(cc1)C(O)=O)C(=O)Cc1c[nH]
c2cc(F)ccc12
N-[1-(4-hydroxyphenyl)propan-2-yl]-3-oxo-3,4-
dihydro-2H-1,4-benzoxazine-8-carboxamide
MPRO -7.626542 CC(Cc1ccc(O)cc1)NC(=O)c1cccc2NC(=
O)COc12
2-{2-[(methylsulfanyl)methyl]-1H-1,3-benzodiazol-
1-yl}-N-({[1,2,4]triazolo[4,3-a]pyridin-3-
yl}methyl)acetamide
MPRO -7.632684 CSCc1nc2ccccc2n1CC(=O)NCc1nnc2cc
ccn12
4-{[2-(2,5-difluorophenyl)-4-hydroxypyrrolidin-1-
yl]methyl}benzamide
MPRO -7.676844 NC(=O)c1ccc(CN2CC(O)CC2c2cc(F)ccc
2F)cc1
3-(2-methyl-2,3-dihydro-1H-inden-2-yl)-1-{1-[4-
(methylsulfamoyl)phenyl]ethyl}urea
MPRO -7.75727 CNS(=O)(=O)c1ccc(cc1)C(C)NC(=O)NC
1(C)Cc2ccccc2C1
5-[2-(4-fluorophenyl)-4-hydroxypyrrolidine-1-
carbonyl]pyridine-2-carboxamide
MPRO -7.718797 NC(=O)c1ccc(cn1)C(=O)N1CC(O)CC1c1
ccc(F)cc1
2-{2-[1-(2-methoxyphenyl)-5-oxopyrrolidin-3-yl]-
1H-1,3-benzodiazol-1-yl}-N-methyl-N-
phenylacetamide
MPRO -7.687013 COc1ccccc1N1CC(CC1=O)c1nc2ccccc2
n1CC(=O)N(C)c1ccccc1
4-(2-{[1-(4-ethoxyphenyl)-1H-1,3-benzodiazol-2-
yl]sulfanyl}acetyl)-3,3-dimethyl-1,2,3,4-
tetrahydroquinoxalin-2-one
MPRO -7.629347
CCOc1ccc(cc1)-
n1c(SCC(=O)N2c3ccccc3NC(=O)C2(C)C
)nc2ccccc12
6-methyl-N-{3-[(1H-pyrazol-1-yl)methyl]phenyl}-
octahydro-1H-pyrrolo[2,3-c]pyridine-1-
carboxamide
MPRO -7.762516 CN1CCC2CCN(C2C1)C(=O)Nc1cccc(Cn
2cccn2)c1
N-cyclopropyl-3-[2-(2,3,4,5,6-
pentafluorophenyl)acetamido]benzamide
MPRO -7.647161 Fc1c(F)c(F)c(CC(=O)Nc2cccc(c2)C(=O)
NC2CC2)c(F)c1F
{[1-(2,4-difluorophenyl)ethyl]carbamoyl}methyl	2-
[3-(4-methoxyphenyl)propanamido]benzoate
MPRO -7.620529 COc1ccc(CCC(=O)Nc2ccccc2C(=O)OCC
(=O)NC(C)c2ccc(F)cc2F)cc1
2-({4-amino-5-[(4-methoxyphenyl)methyl]-4H-
1,2,4-triazol-3-yl}sulfanyl)-N-(3,5-dimethylphenyl)-
2-phenylacetamide
MPRO -7.684616 COc1ccc(Cc2nnc(SC(C(=O)Nc3cc(C)cc(
C)c3)c3ccccc3)n2N)cc1
{7-[(ethoxycarbonyl)amino]-2-oxo-2H-chromen-4-
yl}methyl	2-(3-bromobenzenesulfonamido)acetate
MPRO -7.636072 CCOC(=O)Nc1ccc2c(COC(=O)CNS(=O)(
=O)c3cccc(Br)c3)cc(=O)oc2c1
5-methyl-N-{3-
[(phenylcarbamoyl)methoxy]phenyl}-2-(4H-1,2,4-
triazol-4-yl)benzamide
MPRO -7.70219 Cc1ccc(c(c1)C(=O)Nc1cccc(OCC(=O)Nc
2ccccc2)c1)-n1cnnc1
[(9,10-dioxo-9,10-dihydroanthracen-1-
yl)carbamoyl]methyl	2-(thiophen-3-yl)acetate
MPRO -7.757383 O=C(COC(=O)Cc1ccsc1)Nc1cccc2C(=O)
c3ccccc3C(=O)c12
2-({[(9,10-dioxo-9,10-dihydroanthracen-1-
yl)carbamoyl]methyl}sulfanyl)pyridin-1-ium-1-olate
MPRO -7.802135
[O-
][n+]1ccccc1SCC(=O)Nc1cccc2C(=O)c3
ccccc3C(=O)c12
[(3-acetylphenyl)carbamoyl](phenyl)methyl	3-
[methyl(phenyl)sulfamoyl]benzoate
MPRO -7.784198
CN(c1ccccc1)S(=O)(=O)c1cccc(c1)C(=O
)OC(C(=O)Nc1cccc(c1)C(C)=O)c1ccccc
1
2-amino-3-nitro-N-{[4-(propan-2-yloxy)-2-
(trifluoromethyl)phenyl]methyl}pyridine-4-
carboxamide
MPRO -7.691484 CC(C)Oc1ccc(CNC(=O)c2ccnc(N)c2[N+]
([O-])=O)c(c1)C(F)(F)F
4-[(4-carbamoylphenyl)methyl]-N-methyl-3,4-
dihydro-2H-1,4-benzoxazine-2-carboxamide
MPRO -7.658907 CNC(=O)C1CN(Cc2ccc(cc2)C(N)=O)c2c
cccc2O1
N-(3-
{[(carbamoylmethyl)carbamoyl]amino}phenyl)-1H-
indole-7-carboxamide
MPRO -7.68726 NC(=O)CNC(=O)Nc1cccc(NC(=O)c2ccc
c3cc[nH]c23)c1
ethyl	2-{2-[(6-ethoxy-1H-1,3-benzodiazol-2-
yl)sulfanyl]propanamido}-6-methyl-4,5,6,7-
tetrahydro-1-benzothiophene-3-carboxylate
MPRO -7.618485 CCOC(=O)c1c(NC(=O)C(C)Sc2nc3ccc(O
CC)cc3[nH]2)sc2CC(C)CCc12
N-[1-(4-fluorophenyl)-3-methyl-1H-pyrazol-5-yl]-2-
{[1,2,4]triazolo[4,3-a]pyridin-3-
ylsulfanyl}acetamide
MPRO -7.703882 Cc1cc(NC(=O)CSc2nnc3ccccn23)n(n1)-
c1ccc(F)cc1
2-phenyl-2-{[1,2,4]triazolo[4,3-a]pyridin-3-
ylsulfanyl}-N-[3-(trifluoromethyl)phenyl]acetamide
MPRO -7.618894 FC(F)(F)c1cccc(NC(=O)C(Sc2nnc3ccccn
23)c2ccccc2)c1
2-(4-hydroxyphenyl)-1-{3-[1-methyl-4-
(trifluoromethyl)-1H-imidazol-2-yl]piperidin-1-
yl}ethan-1-one
MPRO -7.722702 Cn1cc(nc1C1CCCN(C1)C(=O)Cc1ccc(O)
cc1)C(F)(F)F
2-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-N-
methyl-N-{[(2R,3S)-1-methyl-2-(1-methyl-1H-
pyrazol-5-yl)piperidin-3-yl]methyl}acetamide
MPRO -7.712632 CN(C[C@@H]1CCCN(C)[C@H]1c1ccnn
1C)C(=O)Cn1ccc(=O)[nH]c1=O
N-(3-carbamoylphenyl)-4-(2-fluorophenyl)-1,4-
diazepane-1-carboxamide
MPRO -7.652268 NC(=O)c1cccc(NC(=O)N2CCCN(CC2)c2
ccccc2F)c1
N-[3-(difluoromethyl)-5-methyl-1H-pyrazol-4-yl]-2-
oxo-1H,2H,3H-imidazo[4,5-b]pyridine-6-
carboxamide
MPRO -7.796011 Cc1[nH]nc(C(F)F)c1NC(=O)c1cnc2[nH]
c(=O)[nH]c2c1
3-(2-oxo-1,2,3,4-tetrahydroquinolin-3-yl)-N-{[4-(2-
oxopyrrolidin-1-yl)phenyl]methyl}propanamide
MPRO -7.747528 O=C(CCC1Cc2ccccc2NC1=O)NCc1ccc(c
c1)N1CCCC1=O
methyl	3-[(7-fluoro-2-oxo-1,2,3,4-
tetrahydroquinolin-4-yl)formamido]-3-
phenylpropanoate
MPRO -7.771538 COC(=O)CC(NC(=O)C1CC(=O)Nc2cc(F)
ccc12)c1ccccc1
5-[3-(4-fluorophenyl)prop-2-enoyl]-2,3-dihydro-1H-
1,3-benzodiazol-2-one
MPRO -7.719031 Fc1ccc(C=CC(=O)c2ccc3[nH]c(=O)[nH]
c3c2)cc1
5-[3-(2,6-dichlorophenyl)prop-2-enoyl]-2,3-dihydro-
1H-1,3-benzodiazol-2-one
MPRO -7.693111 Clc1cccc(Cl)c1C=CC(=O)c1ccc2[nH]c(=
O)[nH]c2c1
N-(3-{[(furan-2-yl)methyl]sulfamoyl}phenyl)-3-(2-
oxo-1,2,3,4-tetrahydroquinolin-3-yl)propanamide
MPRO -7.706308 O=C(CCC1Cc2ccccc2NC1=O)Nc1cccc(c
1)S(=O)(=O)NCc1ccco1
N-{3-[5-(2-fluorophenyl)-1-(2-methoxyacetyl)-4,5-
dihydro-1H-pyrazol-3-
yl]phenyl}methanesulfonamide
MPRO -7.733552 COCC(=O)N1N=C(CC1c1ccccc1F)c1ccc
c(NS(C)(=O)=O)c1
4-[2-(4-chloro-2-nitrophenoxy)acetyl]-1,2,3,4-
tetrahydroquinoxalin-2-one
MPRO -7.749496
[O-
][N+](=O)c1cc(Cl)ccc1OCC(=O)N1CC(=
O)Nc2ccccc12
2-(4-fluorobenzenesulfonamido)-N-[3-(2-
oxopyrrolidin-1-yl)phenyl]benzamide
MPRO -7.643129 Fc1ccc(cc1)S(=O)(=O)Nc1ccccc1C(=O)
Nc1cccc(c1)N1CCCC1=O
1-[(2-chloro-4-nitrophenyl)carbamoyl]ethyl	2-[(4-
tert-butylphenyl)formamido]-4-
(methylsulfanyl)butanoate
MPRO -7.697784
CSCCC(NC(=O)c1ccc(cc1)C(C)(C)C)C(=
O)OC(C)C(=O)Nc1ccc(cc1Cl)[N+]([O-
])=O
N-{2-[hydroxy(pyridin-2-yl)methyl]phenyl}-7-
methoxy-1,2,3,4-tetrahydronaphthalene-1-
carboxamide
MPRO -7.680547 COc1ccc2CCCC(C(=O)Nc3ccccc3C(O)c
3ccccn3)c2c1
N-(3-cyanophenyl)-3-[(4-
methoxyphenyl)(methyl)sulfamoyl]benzamide
MPRO -7.608325 COc1ccc(cc1)N(C)S(=O)(=O)c1cccc(c1)
C(=O)Nc1cccc(c1)C#N
3-benzyl-4-oxo-N-[1-(4-sulfamoylphenyl)ethyl]-3,4-
dihydrophthalazine-1-carboxamide
MPRO -7.71278 CC(NC(=O)c1nn(Cc2ccccc2)c(=O)c2ccc
cc12)c1ccc(cc1)S(N)(=O)=O
2-{[2-(2-methyl-2,3-dihydro-1H-indol-1-yl)-2-
oxoethyl]sulfanyl}quinoline-4-carboxamide
MPRO -7.642768 CC1Cc2ccccc2N1C(=O)CSc1cc(C(N)=O)
c2ccccc2n1
N-cyclopropyl-3-{[2-(2,2-dimethyl-3-oxo-1,2,3,4-
tetrahydroquinoxalin-1-yl)-2-oxoethyl]amino}-4-
methoxybenzene-1-sulfonamide
MPRO -7.783271 COc1ccc(cc1NCC(=O)N1c2ccccc2NC(=
O)C1(C)C)S(=O)(=O)NC1CC1
N'-benzyl-N-[({2-[(3-
methylphenyl)carbamoyl]phenyl}carbamoyl)methy
l]ethanediamide
MPRO -7.640353 Cc1cccc(NC(=O)c2ccccc2NC(=O)CNC(=
O)C(=O)NCc2ccccc2)c1
N-(3-cyclopropyl-1-phenyl-1H-pyrazol-5-yl)-2-
{2,4,5,7-tetraazatricyclo[6.4.0.0²,⁶]dodeca-
1(12),3,5,8,10-pentaen-3-ylsulfanyl}acetamide
MPRO -7.809379 O=C(CSc1nnc2[nH]c3ccccc3n12)Nc1cc
(nn1-c1ccccc1)C1CC1
N-[3-(N',N'-diphenylhydrazinecarbonyl)phenyl]-2-
[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]acetamide
MPRO -7.719529 Cn1cnnc1SCC(=O)Nc1cccc(c1)C(=O)N
N(c1ccccc1)c1ccccc1
N-{[4-(dimethylamino)phenyl]methyl}-N-methyl-2-
[(2-oxo-1,2,3,4-tetrahydroquinolin-6-
yl)oxy]acetamide
MPRO -7.769056 CN(C)c1ccc(CN(C)C(=O)COc2ccc3NC(=
O)CCc3c2)cc1
3-[3-(1,3-benzothiazol-2-yl)piperidine-1-carbonyl]-
1-phenyl-4,5-dihydro-1H-pyrazole-5-carboxamide
MPRO -7.602391 NC(=O)C1CC(=NN1c1ccccc1)C(=O)N1C
CCC(C1)c1nc2ccccc2s1
(2-{[(2-methylphenyl)carbamoyl]methyl}-1,3-
thiazol-4-yl)methyl	5-carbamoyl-1-phenyl-4,5-
dihydro-1H-pyrazole-3-carboxylate
MPRO -7.69133 Cc1ccccc1NC(=O)Cc1nc(COC(=O)C2=N
N(C(C2)C(N)=O)c2ccccc2)cs1
N-{3-[1-({[1-(3-
fluorophenyl)ethyl]carbamoyl}amino)ethyl]phenyl}
acetamide
MPRO -7.802171 CC(NC(=O)NC(C)c1cccc(NC(C)=O)c1)c1
cccc(F)c1
N-{3-[1-({[(2,5-
dimethoxyphenyl)methyl]carbamoyl}amino)ethyl]p
henyl}acetamide
MPRO -7.721882 COc1ccc(OC)c(CNC(=O)NC(C)c2cccc(N
C(C)=O)c2)c1
N-[(2-ethoxypyridin-3-yl)methyl]-2-[2-methyl-4-(4-
methylphenyl)-1,3-thiazol-5-yl]acetamide
MPRO -7.648012 CCOc1ncccc1CNC(=O)Cc1sc(C)nc1-
c1ccc(C)cc1
N-[(2,3-dihydro-1-benzofuran-2-yl)methyl]-2-oxo-
1,2,3,4-tetrahydroquinoline-6-carboxamide
MPRO -7.632513 O=C(NCC1Cc2ccccc2O1)c1ccc2NC(=O)
CCc2c1
3-{3-cyclopropyl-1-[2-(pyridin-4-yl)acetyl]pyrrolidin-
2-yl}-4-methyl-4,5-dihydro-1H-1,2,4-triazol-5-one
MPRO -7.675123 Cn1c(n[nH]c1=O)C1C(CCN1C(=O)Cc1c
cncc1)C1CC1
2-[(3,4-dichlorophenyl)methyl]-N-({4-oxo-4H-
pyrido[1,2-a]pyrimidin-2-yl}methyl)-2,7-
diazaspiro[4.5]decane-7-carboxamide
MPRO -7.628686 Clc1ccc(CN2CCC3(C2)CCCN(C3)C(=O)N
Cc2cc(=O)n3ccccc3n2)cc1Cl
N-{4-[1-({[(2H-1,3-benzodioxol-5-
yl)methyl]carbamoyl}amino)ethyl]phenyl}propana
mide
MPRO -7.656456 CCC(=O)Nc1ccc(cc1)C(C)NC(=O)NCc1c
cc2OCOc2c1
N-{4-[1-({[(2,3-dihydro-1,4-benzodioxin-6-
yl)methyl]carbamoyl}amino)ethyl]phenyl}propana
mide
MPRO -7.740255 CCC(=O)Nc1ccc(cc1)C(C)NC(=O)NCc1c
cc2OCCOc2c1
N-[3-(3-carbamoyl-1H-pyrazol-1-yl)phenyl]-1-(2-
phenylethenesulfonyl)piperidine-4-carboxamide
MPRO -7.715121
NC(=O)c1ccn(n1)-
c1cccc(NC(=O)C2CCN(CC2)S(=O)(=O)C
=Cc2ccccc2)c1
N-(3-cyanophenyl)-2-[4-(3-phenylprop-2-en-1-
yl)piperazin-1-yl]propanamide
MPRO -7.756551 CC(N1CCN(CC=Cc2ccccc2)CC1)C(=O)N
c1cccc(c1)C#N
4-methyl-5-{2-[(4-oxo-3-propyl-3,4-
dihydroquinazolin-2-yl)sulfanyl]acetyl}-2,3,4,5-
tetrahydro-1H-1,5-benzodiazepin-2-one
MPRO -7.768639 CCCn1c(SCC(=O)N2C(C)CC(=O)Nc3ccc
cc23)nc2ccccc2c1=O
N-[3,5-bis(trifluoromethyl)phenyl]-2-(2-oxo-1,2-
dihydropyridin-1-yl)acetamide
MPRO -7.623712 FC(F)(F)c1cc(NC(=O)Cn2ccccc2=O)cc(c
1)C(F)(F)F
N-[1-(2,3-dihydro-1,4-benzodioxin-6-yl)ethyl]-2-[4-
(N-methyl4-
methylbenzenesulfonamido)phenoxy]acetamide
MPRO -7.61314 CC(NC(=O)COc1ccc(cc1)N(C)S(=O)(=O)
c1ccc(C)cc1)c1ccc2OCCOc2c1
N-(2-{2,4-dioxo-3-azatricyclo[7.3.1.0⁵,¹³]trideca-
1(13),5,7,9,11-pentaen-3-yl}ethyl)-N-(3-
fluorophenyl)pyridine-3-carboxamide
MPRO -7.63636 Fc1cccc(c1)N(CCN1C(=O)c2cccc3cccc(
C1=O)c23)C(=O)c1cccnc1
N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)-2-
(thiophen-2-yl)quinoline-4-carboxamide
MPRO -7.800731 O=C(Nc1cccc2C(=O)c3ccccc3C(=O)c12
)c1cc(nc2ccccc12)-c1cccs1
[(9,10-dioxo-9,10-dihydroanthracen-1-
yl)carbamoyl]methyl	5-oxopyrrolidine-2-
carboxylate
MPRO -7.792261 O=C(COC(=O)C1CCC(=O)N1)Nc1cccc2
C(=O)c3ccccc3C(=O)c12
N-(2,6-dimethylphenyl)-2-[(5-{3-[(4-
methoxyphenyl)sulfamoyl]phenyl}-4-(6-
methylheptan-2-yl)-4H-1,2,4-triazol-3-
yl)sulfanyl]acetamide
MPRO -7.635464
COc1ccc(NS(=O)(=O)c2cccc(c2)-
c2nnc(SCC(=O)Nc3c(C)cccc3C)n2C(C)C
CCC(C)C)cc1
2-methoxy-4-{[(4-
methoxybenzenesulfonamido)imino]methyl}pheny
l	N-phenylcarbamate
MPRO -7.623766 COc1ccc(cc1)S(=O)(=O)NN=Cc1ccc(OC
(=O)Nc2ccccc2)c(OC)c1
[(2,3-dimethylcyclohexyl)carbamoyl]methyl	5-
(benzylsulfamoyl)-2-hydroxybenzoate
MPRO -7.691032 CC1CCCC(NC(=O)COC(=O)c2cc(ccc2O)
S(=O)(=O)NCc2ccccc2)C1C
4-fluoro-3-({[2-(2-oxopyrrolidin-1-yl)-1-
phenylethyl]carbamoyl}amino)benzamide
MPRO -7.779582 NC(=O)c1ccc(F)c(NC(=O)NC(CN2CCCC
2=O)c2ccccc2)c1
2-({[(4-fluorophenyl)carbamoyl]methyl}sulfanyl)-N-
({[1,2,4]triazolo[4,3-a]pyridin-3-
yl}methyl)benzamide
MPRO -7.678648 Fc1ccc(NC(=O)CSc2ccccc2C(=O)NCc2n
nc3ccccn23)cc1
3-({[(2,3-dihydro-1,4-benzodioxin-2-
yl)methyl]carbamoyl}methyl)-4-oxo-3,4-
dihydrophthalazine-1-carboxamide
MPRO -7.677514 NC(=O)c1nn(CC(=O)NCC2COc3ccccc3
O2)c(=O)c2ccccc12
1-[(4-carbamoylphenyl)methyl]-2-methyl-1,2,3,4-
tetrahydroquinoline-4-carboxamide
MPRO -7.686286 CC1CC(C(N)=O)c2ccccc2N1Cc1ccc(cc1
)C(N)=O
2-[(4-fluorophenyl)methyl]-3-{[6-oxo-1-(2-
phenoxyethyl)-1,6-dihydropyridazin-3-
yl]formamido}propanamide
MPRO -7.656212 NC(=O)C(CNC(=O)c1ccc(=O)n(CCOc2c
cccc2)n1)Cc1ccc(F)cc1
3-({[3-(1-cyclopropyl-1H-1,2,3,4-tetrazol-5-
yl)phenyl]carbamoyl}amino)-2-[(4-
ethoxyphenyl)methyl]propanamide
MPRO -7.739139 CCOc1ccc(CC(CNC(=O)Nc2cccc(c2)-
c2nnnn2C2CC2)C(N)=O)cc1
N-[(1,3-diphenyl-1H-pyrazol-4-yl)methyl]-2-methyl-
5-sulfamoylbenzamide
MPRO -7.629789 Cc1ccc(cc1C(=O)NCc1cn(nc1-
c1ccccc1)-c1ccccc1)S(N)(=O)=O
N-(3-carbamoylphenyl)-1H-indole-3-carboxamide MPRO -7.65138 NC(=O)c1cccc(NC(=O)c2c[nH]c3ccccc2
3)c1
N-[1-(1,3-benzothiazol-2-yl)ethyl]-2-({[(3-
cyanophenyl)carbamoyl]methyl}sulfanyl)-N-
methylbenzamide
MPRO -7.604902 CC(N(C)C(=O)c1ccccc1SCC(=O)Nc1ccc
c(c1)C#N)c1nc2ccccc2s1
2-{3-[(cyclooctylcarbamoyl)methyl]-2,4-dioxo-
1,2,3,4-tetrahydropyrimidin-1-yl}-N-(nonan-4-
yl)acetamide
MPRO -7.685229 CCCCCC(CCC)NC(=O)Cn1ccc(=O)n(CC(
=O)NC2CCCCCCC2)c1=O
5-tert-butyl-N-[5-chloro-2-(1H-1,2,4-triazol-1-
yl)phenyl]-2-methylbenzene-1-sulfonamide
MPRO -7.628456 Cc1ccc(cc1S(=O)(=O)Nc1cc(Cl)ccc1-
n1cncn1)C(C)(C)C
({2-[(2H-1,3-benzodioxol-5-
yl)carbamoyl]phenyl}carbamoyl)methyl	4-oxo-3,4-
dihydrophthalazine-1-carboxylate
MPRO -7.796552 O=C(COC(=O)c1n[nH]c(=O)c2ccccc12)
Nc1ccccc1C(=O)Nc1ccc2OCOc2c1
6-amino-5-(2-{[3-(3-chloro-2-methylphenyl)-4-oxo-
3,4-dihydroquinazolin-2-yl]sulfanyl}acetyl)-1-
methyl-1,2,3,4-tetrahydropyrimidine-2,4-dione
MPRO -7.617443
Cc1c(Cl)cccc1-
n1c(SCC(=O)c2c(N)n(C)c(=O)[nH]c2=O
)nc2ccccc2c1=O
5-chloro-2-{2-[2-(2,3-dihydro-1,4-benzodioxin-6-
yl)pyrrolidin-1-yl]-2-oxoethoxy}benzamide
MPRO -7.637594 NC(=O)c1cc(Cl)ccc1OCC(=O)N1CCCC1
c1ccc2OCCOc2c1
{4-oxo-4H-pyrido[1,2-a]pyrimidin-2-yl}methyl	3-(4-
methylbenzenesulfonyl)propanoate
MPRO -7.770157 Cc1ccc(cc1)S(=O)(=O)CCC(=O)OCc1cc(
=O)n2ccccc2n1
{4-oxo-4H-pyrido[1,2-a]pyrimidin-2-yl}methyl	3-
(benzyloxy)benzoate
MPRO -7.60401 O=C(OCc1cc(=O)n2ccccc2n1)c1cccc(O
Cc2ccccc2)c1
N-(6-fluoro-2,3-dihydro-1H-inden-1-yl)-N'-[3-
(methylsulfanyl)phenyl]ethanediamide
TMPRSS2 -7.129755 CSc1cccc(NC(=O)C(=O)NC2CCc3ccc(F)
cc23)c1
N-(2-hydroxy-2-phenylpropyl)-5-methyl-1-
benzofuran-2-carboxamide
TMPRSS2 -7.090923 Cc1ccc2oc(cc2c1)C(=O)NCC(C)(O)c1cc
ccc1
2-(3-fluorophenyl)-N-{[(2-hydroxy-2,3-dihydro-1H-
inden-1-yl)carbamoyl]methyl}acetamide
TMPRSS2 -7.083628 OC1Cc2ccccc2C1NC(=O)CNC(=O)Cc1c
ccc(F)c1
3-(3-cyanophenyl)-N-(2-hydroxy-2-
phenylpropyl)prop-2-enamide
TMPRSS2 -7.100698 CC(O)(CNC(=O)C=Cc1cccc(c1)C#N)c1c
cccc1
N-[2-(1-benzothiophen-2-yl)-2-hydroxyethyl]-2-[2-
(3-fluorophenyl)acetamido]acetamide
TMPRSS2 -7.173833 OC(CNC(=O)CNC(=O)Cc1cccc(F)c1)c1c
c2ccccc2s1
N-[2-(5-fluoro-1H-indol-3-yl)ethyl]imidazo[1,2-
a]pyridine-3-carboxamide
TMPRSS2 -7.082199 Fc1ccc2[nH]cc(CCNC(=O)c3cnc4ccccn
34)c2c1
N'-[(1,3-dimethyl-2,4-dioxo-1,2,3,4-
tetrahydropyrimidin-5-yl)sulfonyl]-2-(4-
ethylphenyl)acetohydrazide
TMPRSS2 -7.112836 CCc1ccc(CC(=O)NNS(=O)(=O)c2cn(C)c(
=O)n(C)c2=O)cc1
N'-(2-methanesulfinyl-1-phenylethyl)-N-[3-(5-
methyl-1H-1,2,4-triazol-3-yl)phenyl]ethanediamide
TMPRSS2 -7.126673
Cc1nc(n[nH]1)-
c1cccc(NC(=O)C(=O)NC(CS(C)=O)c2ccc
cc2)c1
N-(6-amino-1-benzyl-2,4-dioxo-1,2,3,4-
tetrahydropyrimidin-5-yl)-2-{[1-benzyl-5-
(trifluoromethyl)-1H-1,3-benzodiazol-2-yl]sulfanyl}-
N-butylacetamide
TMPRSS2 -7.099033
CCCCN(C(=O)CSc1nc2cc(ccc2n1Cc1ccc
cc1)C(F)(F)F)c1c(N)n(Cc2ccccc2)c(=O)[
nH]c1=O
2-oxo-2-(1,2,3,4-tetrahydroquinolin-1-yl)ethyl	2-
(3,4-dimethylbenzenesulfonamido)acetate
TMPRSS2 -7.148417 Cc1ccc(cc1C)S(=O)(=O)NCC(=O)OCC(=
O)N1CCCc2ccccc12
(4-aminoquinazolin-2-yl)methyl	2-(2,3,4-
trifluorobenzenesulfonamido)acetate
TMPRSS2 -7.160395 Nc1nc(COC(=O)CNS(=O)(=O)c2ccc(F)c(
F)c2F)nc2ccccc12
N-[2-(2,4-difluorophenyl)-2-hydroxypropyl]-2-
(oxan-4-yl)-1,3-oxazole-4-carboxamide
TMPRSS2 -7.159434 CC(O)(CNC(=O)c1coc(n1)C1CCOCC1)c
1ccc(F)cc1F
1-oxo-1-(1,2,3,4-tetrahydroquinolin-1-yl)propan-2-
yl	2-(1H-indol-3-yl)acetate
TMPRSS2 -7.120618 CC(OC(=O)Cc1c[nH]c2ccccc12)C(=O)N
1CCCc2ccccc12
5-hydroxy-N-(2-hydroxy-4-phenylbutyl)-1,2,3,4-
tetrahydronaphthalene-1-carboxamide
TMPRSS2 -7.139395 OC(CCc1ccccc1)CNC(=O)C1CCCc2c(O)
cccc12
1-{6-bromo-2-methylimidazo[1,2-a]pyridine-3-
carbonyl}azetidin-3-ol
TMPRSS2 -7.004282 Cc1nc2ccc(Br)cn2c1C(=O)N1CC(O)C1
3-[3-(2,5-dichlorophenoxy)-2-hydroxypropyl]-7-
fluoro-3,4-dihydroquinazolin-4-one
TMPRSS2 -7.190593 OC(COc1cc(Cl)ccc1Cl)Cn1cnc2cc(F)ccc
2c1=O
1-(ethanesulfonyl)-N-[(2-hydroxynaphthalen-1-
yl)(phenyl)methyl]piperidine-4-carboxamide
TMPRSS2 -7.089504 CCS(=O)(=O)N1CCC(CC1)C(=O)NC(c1cc
ccc1)c1c(O)ccc2ccccc12
N-{[2-(1H-imidazol-1-yl)phenyl]methyl}-1,2-
dimethyl-1H-indole-3-sulfonamide
TMPRSS2 -7.124544 Cc1c(c2ccccc2n1C)S(=O)(=O)NCc1cccc
c1-n1ccnc1
3-(1H-indol-3-yl)-2-({[(2-
methylphenyl)methyl]carbamoyl}amino)propanoic	
acid
TMPRSS2 -7.196331 Cc1ccccc1CNC(=O)NC(Cc1c[nH]c2cccc
c12)C(O)=O
2-(1H-indol-3-yl)-2-oxoethyl	2-
benzenesulfonamidoacetate
TMPRSS2 -7.106572 O=C(CNS(=O)(=O)c1ccccc1)OCC(=O)c1
c[nH]c2ccccc12
[(2H-1,3-benzodioxol-5-yl)carbamoyl]methyl	2-[2-
(3,4-
dimethylbenzenesulfonamido)acetamido]acetate
TMPRSS2 -7.118744 Cc1ccc(cc1C)S(=O)(=O)NCC(=O)NCC(=
O)OCC(=O)Nc1ccc2OCOc2c1
2,5-difluoro-N-{3-hydroxy-2-[(pyridin-3-
yl)methyl]propyl}benzene-1-sulfonamide
TMPRSS2 -7.123749 OCC(CNS(=O)(=O)c1cc(F)ccc1F)Cc1ccc
nc1
N-cyclopropyl-2-{3-[(1,3-dioxo-2,3-dihydro-1H-
isoindol-2-yl)methyl]benzamido}benzamide
TMPRSS2 -7.180751 O=C(Nc1ccccc1C(=O)NC1CC1)c1cccc(C
N2C(=O)c3ccccc3C2=O)c1
N-(4-fluorophenyl)-3-[2-
(trifluoromethyl)benzenesulfonamido]propanamid
e
TMPRSS2 -7.088645 Fc1ccc(NC(=O)CCNS(=O)(=O)c2ccccc2
C(F)(F)F)cc1
1-(2,5-dichlorophenoxy)-3-[5-(4-methylphenyl)-2H-
1,2,3,4-tetrazol-2-yl]propan-2-ol
TMPRSS2 -7.115764 Cc1ccc(cc1)-
c1nnn(CC(O)COc2cc(Cl)ccc2Cl)n1
4-{2-[3-(2,4-dichlorophenoxy)-2-hydroxypropyl]-2H-
1,2,3,4-tetrazol-5-yl}benzamide
TMPRSS2 -7.113681 NC(=O)c1ccc(cc1)-
c1nnn(CC(O)COc2ccc(Cl)cc2Cl)n1
1-[2-(3-fluorophenyl)-2-hydroxypropyl]-3-
{5H,7H,8H-pyrano[4,3-b]pyridin-3-yl}urea
TMPRSS2 -7.095425 CC(O)(CNC(=O)Nc1cnc2CCOCc2c1)c1c
ccc(F)c1
2-(3-fluorobenzenesulfonamido)-N-(4-
sulfamoylphenyl)acetamide
TMPRSS2 -7.139361 NS(=O)(=O)c1ccc(NC(=O)CNS(=O)(=O)
c2cccc(F)c2)cc1
N-(3,4-dimethoxyphenyl)-2-(3,4-
dimethylbenzenesulfonamido)acetamide
TMPRSS2 -7.113242 COc1ccc(NC(=O)CNS(=O)(=O)c2ccc(C)
c(C)c2)cc1OC
2-(2-fluorobenzenesulfonamido)-N-[3-(propan-2-
yl)phenyl]propanamide
TMPRSS2 -7.193332 CC(C)c1cccc(NC(=O)C(C)NS(=O)(=O)c2
ccccc2F)c1
N-[3-(2,4-difluorophenyl)-1-methyl-1H-pyrazol-5-
yl]-2-(3,4,5-trifluorophenyl)cyclopropane-1-
carboxamide
TMPRSS2 -7.139957 Cn1nc(cc1NC(=O)C1CC1c1cc(F)c(F)c(F)
c1)-c1ccc(F)cc1F
2-(1H-1,3-benzodiazol-1-yl)-N-[2-(3-
chlorobenzenesulfonamido)ethyl]propanamide
TMPRSS2 -7.125183 CC(C(=O)NCCNS(=O)(=O)c1cccc(Cl)c1)
n1cnc2ccccc12
N'-(3-methyl-1-phenylbutyl)-N-(quinolin-6-
yl)ethanediamide
TMPRSS2 -7.149125 CC(C)CC(NC(=O)C(=O)Nc1ccc2ncccc2c
1)c1ccccc1
2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-4-yl)-N'-[3-
(trifluoromethyl)benzenesulfonyl]acetohydrazide
TMPRSS2 -7.143432 FC(F)(F)c1cccc(c1)S(=O)(=O)NNC(=O)C
N1C(=O)COc2ccccc12
2-(4-bromobenzenesulfonamido)-N-[1,3-dihydroxy-
1-(4-nitrophenyl)propan-2-yl]benzamide
TMPRSS2 -7.119263 OCC(NC(=O)c1ccccc1NS(=O)(=O)c1ccc
(Br)cc1)C(O)c1ccc(cc1)[N+]([O-])=O
2-oxo-N-(3-{3-oxo-2H,3H-[1,2,4]triazolo[4,3-
a]pyridin-2-yl}propyl)-2,3,4,5-tetrahydro-1H-1-
benzazepine-7-carboxamide
TMPRSS2 -7.104517 O=C(NCCCn1nc2ccccn2c1=O)c1ccc2N
C(=O)CCCc2c1
methyl	3-(3-bromophenyl)-3-{[(4-
ethoxyphenyl)carbamoyl]formamido}propanoate
TMPRSS2 -7.082909 CCOc1ccc(NC(=O)C(=O)NC(CC(=O)OC)
c2cccc(Br)c2)cc1
N'-[1,2-bis(3-fluorophenyl)ethyl]-N-[4-
(cyanomethoxy)phenyl]ethanediamide
TMPRSS2 -7.198013 Fc1cccc(CC(NC(=O)C(=O)Nc2ccc(OCC#
N)cc2)c2cccc(F)c2)c1
N-[2-(2,4-difluorobenzenesulfonamido)ethyl]-2-(4-
fluorophenyl)acetamide
TMPRSS2 -7.121373 Fc1ccc(CC(=O)NCCNS(=O)(=O)c2ccc(F)
cc2F)cc1
{[2-(2-methoxyphenyl)ethyl]carbamoyl}methyl	2-(4-
carbamoyl-1-oxo-1,2-dihydrophthalazin-2-
yl)acetate
TMPRSS2 -7.108118 COc1ccccc1CCNC(=O)COC(=O)Cn1nc(
C(N)=O)c2ccccc2c1=O
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